

## *Curriculum vitae*

**Date Prepared:** July 1, 2021

**Name:** Amit Singal

**Office Address:** Division of Digestive and Liver Diseases  
University of Texas Southwestern  
5959 Harry Hines Blvd POB1 Suite 420B  
Dallas TX 75390-8887

**Work Phone:** 214-645-6216

**Work E-Mail:** amit.singal@utsouthwestern.edu

**Work Fax:** 214-645-6294

**Place of Birth:** Perth Amboy, New Jersey

### **Education**

<b>Year</b>	<b>Degree (Honors)</b>	<b>Field of Study (Thesis advisor for PhDs)</b>	<b>Institution</b>
1995 – 1999	Bachelor of Science with High Distinction (Honors)	Biology	University of Michigan, Ann Arbor, MI
1999 – 2003	Doctor of Medicine	Medicine	University of Michigan, Ann Arbor, MI
2008 – 2009	Masters of Science	Robert Wood Johnson Masters in Health and Health Care Research	University of Michigan, Ann Arbor, MI
2010 – 2013	Masters of Science	Clinical Science with Distinction	University of Texas Southwestern, Dallas, TX

### **Postdoctoral Training**

<b>Year(s)</b>	<b>Titles</b>	<b>Specialty/Discipline (Lab PI for postdoc research)</b>	<b>Institution</b>
2003 – 2006	Resident	Internal Medicine Residency	University of Washington, Seattle, WA
2006 – 2009	Fellow	Gastroenterology Fellowship	University of Michigan, Ann Arbor, MI
2009 – 2010	Fellow	Advanced Hepatology Fellowship	University of Michigan, Ann Arbor, MI

## **Current Licensure and Certification**

### Licensure

2010 Texas Medical Board License

### Board and Other Certification

2006 Board Certification in Internal Medicine, American Board of Internal Medicine

2009 Board Certification in Gastroenterology, American Board of Internal Medicine

2010 Board Certification in Transplant Hepatology, American Board of Internal Medicine

2019 Board Certification in Gastroenterology, American Board of Internal Medicine

## **Honors and Awards**

<b>Year</b>	<b>Name of Honor/Award</b>	<b>Awarding Organization</b>
2002	Alpha Omega Alpha	Alpha Omega Alpha Honor Medical Society
2006	Huesby Teaching Award	University of Washington Medical Center
2008	Phi Kappa Phi	Phi Kappa Phi National Honor Society
2009	Advanced Transplant Hepatology Fellowship Award	American Association for Study of the Liver (AASLD)
2010	Academic Skills Workshop	American Gastroenterological Association (AGA)
2010	Dedman Family Scholar in Clinical Care	UT Southwestern Medical Center
2012	Lyman Bilhartz Memorial Teaching Award	UT Southwestern Medical Center
2013	Junior Investigator Award	International Liver Cancer Association
2015	Young Investigator Award	American Gastroenterological Association (AGA)
2017	Blue Faery Award for Excellence in Liver Cancer Research	Blue Faery: Adrienne Wilson Liver Cancer Association
2018	Internal Medicine Outstanding Research Mentor	UT Southwestern Medical Center
2019	Outstanding Mentor Award	Center for Translational Medicine, UT Southwestern Medical Center
2020	Internal Medicine Outstanding Research Mentor	UT Southwestern Medical Center
2020	Best Doctor 2020	D Magazine
2021	Internal Medicine Outstanding Research Mentor	UT Southwestern Medical Center
2021	Best Doctor 2021	D Magazine

## **Faculty Academic Appointments**

<b>Year(s)</b>	<b>Academic Title</b>	<b>Department</b>	<b>Academic Institution</b>
2010	Assistant Professor of Internal Medicine	Dept of Internal Medicine	UT Southwestern Medical Center
2015	Adjunct Instructor	Dept of Health Policy and Management	Texas A&M University School of Public Health
2015	Associate Professor of Internal Medicine	Dept of Internal Medicine	UT Southwestern Medical Center
2017	David Bruton Professorship in Clinical Cancer Research	Dept of Internal Medicine	UT Southwestern Medical Center
2019	Professor of Internal Medicine	Dept of Internal Medicine	UT Southwestern Medical Center

**Appointments at Hospitals/Affiliated Institutions**

<b>Year(s)</b>	<b>Position Title</b>	<b>Department/Division</b>	<b>Institution</b>
2010	Staff Physician	Digestive and Liver Diseases	UT Southwestern Medical Center
2010	Staff Physician	Digestive and Liver Diseases	Parkland Health and Hospital System

**Major Administrative/Leadership Positions**

<b>Year(s)</b>	<b>Position Title</b>	<b>Institution</b>
2010 –	Medical Director, Liver Tumor Program	Parkland Health and Hospital System
2012 –	Medical Director, Liver Tumor Program	UT Southwestern Medical Center
2016 –	Clinical Chief of Hepatology	UT Southwestern Medical Center
2017-2018	Program Director, Gastroenterology Fellowship Program	UT Southwestern Medical Center
2019 –	Co-leader of Simmons Cancer Center Population Science and Cancer Control	UT Southwestern Medical Center

**Committee Service** (*Member, unless noted otherwise*)

<b>Year(s)</b>	<b>Name of Committee</b>	<b>Institution/Organization</b>
<b><u>UTSW</u></b>		
2012 - 2018	Chair, Gastroenterology Fellowship Research Committee	UT Southwestern Medical Center
2012 - present	Protocol Review and Monitoring Committee	UT Southwestern Simmons Cancer Center
2012 - 2013	Co-Chair, Gastroenterology Fellowship Education Committee	UT Southwestern Medical Center

2012 - 2013	Co-Director, “Controversies in Gastroenterology and Hepatology” UT Southwestern Symposium	UT Southwestern Medical Center
2012 –	Interviewer, Gastroenterology Fellowship Interviews	UT Southwestern Medical Center
2017 - 2018	Co-Director, “Annual Update in Hepatology” UT Southwestern Symposium	UT Southwestern Medical Center
2019 – present	Dedman Scholars Program Committee	UT Southwestern Medical Center
<b><u>Hospital</u></b>		
2012 - present	GI-Liver Pharmacy & Therapeutics Committee	Parkland Health and Hospital System
<b><u>State/Regional</u></b>		
2019 - present	Texas Collaborative Center for Hepatocellular Carcinoma (TeCH) Steering Committee	CPRIT Collaborative Action Plan Coordinating Center
<b><u>National/International</u></b>		
2018 - present	Publications committee	TARGET-HCC
2018 - present	Steering committee	TARGET-HCC

### **Professional Societies**

<b>Dates</b>	<b>Society Name, member</b>
2006 – present	American Gastroenterological Association (AGA)
2006 – present	American College of Gastroenterology (ACG)
2006 – present	American Association for the Study of Liver Diseases (AASLD)
2007 – present	International Liver Cancer Association (ILCA)
<b><i>Committees</i></b>	
2011 – present	Chair, AGA DDW Abstract Review Committee for Liver and Biliary Carcinoma
2011 – 2015	Chair, AGA DDW Abstract Review Committee for Clinical Biliary Tract Disorders
2012 – present	Member, ILCA Surveillance and Biomarkers Special Interest Group
2013 – present	Member, DDW Abstract Review Committee for AASLD Hepatobiliary Neoplasia
2013 – 2019	Member, AASLD Practice Guidelines Committee
2014 – present	Member, AASLD Hepatobiliary Neoplasia Special Interest Group
2014 – present	Member, AASLD Abstract Review Committee for Hepatobiliary Neoplasia; Biomarkers; Clinical Hepatocellular Carcinoma and Cholangiocarcinoma
2014 – 2019	Chair, ILCA Surveillance and Biomarkers Special Interest Group
2015 – 2017	Member, AGA Liver Disease Measures Workgroup
2015 – 2017	Steering Committee, Public Health/Health Care Delivery Special Interest Group
2015 – 2016	Member, AGA DDW Abstract Review Committee for Clinical Practice- Health Disparities
2017 – 2019	Vice Chair, AASLD Practice Guidelines Committee

2017 - present	Research Committee, American College of Gastroenterology
2018 - 2020	Research Committee, American Association for the Study of Liver Diseases
2018 – present	Education Committee, International Liver Cancer Association
2018 – present	Governing Board, International Liver Cancer Association
2019 – 2023	Steering Committee, American College of Radiology Committee on LI-RADS
2020 – present	Founding co-organizer, HCC-TAG
2021 – 2021	AASLD Hepatobiliary Neoplasia SIG, Vice-Chair
2021 – 2022	AASLD Hepatobiliary Neoplasia SIG, Chair
<b><i>Fellowships</i></b>	
2019	Fellow, American Association for the Study of Liver Diseases (AASLD)

### **Grant Review Activities**

<b>Year(s)</b>	<b>Name of Review Committee</b>	<b>Organization</b>
2011	American Cancer Society Intramural Disparities Cancer Research Grant	UT Southwestern Medical Center
2014	Instituto Toscano Tumori Research Grant	Instituto Toscano Tumori (ITT), Tuscany Italy
2014	Cancer Research UK – Early Diagnosis Advisory Group	Cancer Research UK
2014	National Institute of Diabetes and Digestive and Kidney Diseases PAR 13-228 (ad hoc)	National Institute of Health
2015 – 2017	Kidney, Nutrition, Obesity, and Diabetes Study Section (ad hoc)	National Institute of Health
2017	American Gastroenterological Association (AGA) Elsevier Pilot and Gut Microbiome Pilot Grant	American Gastroenterological Association (AGA)
2017 – 2019	Cancer Biomarkers Study Section (ad hoc)	National Institute of Health
2018 – 2020	American Association for Study of Liver Diseases (AASLD) grant review	American Association for Study of Liver Diseases (AASLD)
2018 – present	American College of Gastroenterology (ACG) grant review	American College of Gastroenterology (ACG)
2019	Canadian Liver Foundation Operating Grant (ad hoc)	Canadian Liver Foundation (CLF)
2019	P20 Special Emphasis Panel Review Group (ad hoc)	National Institute of Health
2021	Therapeutic Indication/Pairing Strategies Special Emphasis Panel (ad hoc)	National Institute of Health
2021	Singapore National Medical Research Council	Singapore Ministry of Health

### **Editorial Activities**

<b>Year(s)</b>	<b>Journal Name</b>
<b><u>Editor/Associate Editor</u></b>	
2015 – 2017	Associate Editor, Clinical and Translational Gastroenterology
2016 – 2018	Hepatic Cancer Section Editor, Current Hepatology Reports
2014 –	PLOS Medicine Academic Editor
2017 – 2021	Seminars in Liver Disease
2017 –	Associate Editor, Clinical Gastroenterology and Hepatology
2018, 2020	Guest Associate Editor, Clinical Liver Disease
<b><u>Editorial Board</u></b>	
2013 – 2017	Clinical Gastroenterology and Hepatology
2018 –	UpToDate Reviewer
2018 –	JHEP Reports
2019 –	Hepatology
<b><u>Ad Hoc Reviewer</u></b>	
2009 –	American Journal of Gastroenterology
2009 –	Digestive Diseases and Sciences
2010 –	Alimentary Pharmacology and Therapeutics
2010 –	Liver Transplantation
2011 –	Gastroenterology
2011 –	Annals of Internal Medicine
2012 –	Hepatology
2012 –	Clinical Gastroenterology and Hepatology
2013 –	PLOS Medicine
2014 –	Journal of Hepatology
2015 –	Lancet Oncology
2015 –	Journal National Cancer Institute
2015 –	New England Journal of Medicine
2017 –	JAMA

### **Grant Support**

<b><u>Present</u></b>	Grantor: National Institute of Health (NIH) R01 CA256977
Grant Title	Multi-level Evaluation of Racial/ethnic disparities in Liver Disease Outcomes
Role	Principal Investigator (MPIs: Singal and Kanwal)
Award dates	12/1/2020 – 11/30/2025

<b><u>Present</u></b>	Grantor: Cancer Prevention Research Institute of Texas (CPRIT)
Grant Title	A Novel Risk Stratification and Early Detection Strategy to Reduce Liver Cancer Mortality
Role	Principal Investigator (PI: Singal)

Award dates	8/31/2020 – 8/30/2025
-------------	-----------------------

<u>Present</u>	Grantor: National Institute of Health (NIH) U01CA230694
Grant Title	Precision Risk Stratification and Screening for HCC among Patients with Cirrhosis in the United States
Role	Principal Investigator (PI: Singal)
Award dates	7/1/18 – 6/30/2023

<u>Present</u>	Grantor: National Institute of Health (NIH) R01CA222900
Grant Title	Precision Screening for Hepatocellular Carcinoma in Patients with Cirrhosis
Role	Principal Investigator (PI: Singal)
Award dates	1/1/18 – 12/31/2022

<u>Present</u>	Grantor: National Institute of Health (NIH) R01CA212008
Grant Title	Harms of Hepatocellular Carcinoma Screening in Patients with Cirrhosis
Role	Principal Investigator (PI: Singal)
Award dates	8/1/17 – 7/31/2023

<u>Present</u>	Grantor: National Institute of Health (NIH) R01MD12565
Grant Title	Multi-level factors for racial/ethnic and socioeconomic disparities in prognosis of Hepatocellular Carcinoma
Role	Principal Investigator (MPIs: Singal and Yopp)
Award dates	4/3/18 – 11/30/2022

<u>Present</u>	Grantor: National Institute of Health (NIH) U01CA226052
Grant Title	Glycopathology of HCC: Identification of the source cells of serum fucosylation
Role	Principal Investigator (MPIs: Mehta, Singal, Drake, Hoshida)
Award dates	3/14/19 – 2/29/2024

<u>Present</u>	Grantor: Cancer Prevention Research Institute of Texas (CPRIT)
Grant Title	Reducing Disparities in Risk of Hepatocellular Carcinoma
Role	Principal Investigator (MPI: Kanwal and Singal)
Award dates	8/31/2020 – 8/30/2025

<u>Present</u>	Grantor: Cancer Prevention Research Institute of Texas (CPRIT)
Grant Title	Genetic Epidemiology of Hepatocellular Carcinoma in Hispanics
Role	Co-Investigator (PI: Thrift)
Award dates	8/31/2020 – 8/30/2025

<u>Present</u>	Grantor: National Institute of Health (NIH) U01CA230997
Grant Title	Risk Stratification and Early Detection of Liver Cancer

Role	Co- Investigator (PI: Kanwal)
Award dates	7/1/18 – 6/30/2023

<u>Present</u>	Grantor: National Institute of Health (NIH) U01CA22573
Grant Title	Screening of Glycan Markers in Serum for Early Detection of HCC in Different Etiologies of Disease
Role	Co-Investigator (PI: Lubman)
Award dates	5/1/18 – 4/30/2022

<u>Present</u>	Grantor: Department of Defense W81XW201416
Grant Title	Portable Point-of-Care Diagnostic Device for Rapid Screening of Hepatitis B
Role	Co-Investigator (PI: deSa)
Award dates	2/1/20 – 1/31/2023

<u>Present</u>	Grantor: Cancer Prevention Research Institute of Texas (CPRIT) RP190641
Grant Title	Texas Collaborative Center for Hepatocellular Cancer Research
Role	Co-investigator (PI: El-Serag)
Award dates	8/31/19 – 8/30/2024

<u>Present</u>	Grantor: National Institute of Health (NIH) P30CA142543
Grant Title	UT Southwestern Simmons Comprehensive Cancer Center
Role	Population Science and Cancer Control Program Leader (PI: Arteaga)
Award dates	8/1/21 – 7/31/2026

<u>Past</u>	Grantor: National Institute of Health (NIH) R01CA215520
Grant Title	Contrast enhanced ultrasound for evaluation of focal liver lesions in patients with cirrhosis or other risk factors for developing HCC
Role	Co-Investigator (PI: Lyshchik)
Award dates	1/1/19 – 8/31/2021

<u>Past</u>	Grantor: Cancer Prevention Research Institute of Texas (CPRIT) PP160075
Grant Title	Implementation of an Evidence-based Colorectal Cancer Screening Program
Role	Co-Principal Investigator (MPIs: Singal and Halm)
Award dates	8/17/16 – 7/31/2021

<u>Past</u>	Grantor: Cancer Prevention Research Institute of Texas (CPRIT) RP150587
Grant Title	Texas Hepatocellular Carcinoma Consortium
Project Title	A randomized controlled trial of strategies to increase HCC surveillance completion among cirrhosis patients in 3 Texas health systems
Role	Project Leader (PI: El-Serag)
Award dates	5/20/15 – 5/31/2020



<u>Past</u>	Grantor: Gilead Pharmaceuticals
Grant Title	Interventions to Increase HCV Testing in a Safety-Net Health System
Role	Principal Investigator (PI: Singal)
Award dates	4/1/17 – 12/31/2020

<u>Past</u>	Grantor: National Institute of Health (NIH) R01CA186566
Grant Title	Genome-Wide Association Study (GWAS) in Hepatocellular Carcinoma
Role	Co-Investigator (PI: Hassan)
Award dates	4/10/15 – 3/31/2020

<u>Past</u>	Grantor: National Institute of Health (NIH) R01CA135069
Grant Title	Glycans in Hepatocellular Carcinoma
Role	Co-Investigator (PI: Goldman)
Award dates	7/1/15 – 7/31/2020

<u>Past</u>	Grantor: Department of Defense W81XWH-16-1-0156
Grant Title	Defining hepatocellular carcinoma subtypes and treatment responses in patient derived tumorgrafts
Role	Principal Investigator (MPIs: Singal, Zhu, Siegwart, Yopp, Waljee)
Award dates	9/1/16 – 8/31/2020

<u>Past</u>	Grantor: National Institute of Health R43 PS005188
Grant Title	Rapid Multiplexed Assay for the Diagnosis of Viral Hepatitis at the Point of Care
Role	Co-Investigator (PI: deSa)
Award dates	10/1/18 – 9/30/2019

<u>Past</u>	Grantor: Abbvie Pharmaceuticals
Grant Title	Association between Direct Acting Antiviral Therapy and HCC Recurrence: A Multi-center North American Cohort Study
Role	Principal Investigator (PI: Singal)
Award dates	1/1/17 – 1/1/2019

<u>Past</u>	Grantor: Cancer Prevention Research Institute of Texas (CPRIT) PP150079
Grant Title	STOP-HCC
Role	Principal Investigator (MPIs: Singal and Turner)
Award dates	6/1/15 – 5/30/2018

<u>Past</u>	Grantor: Agency for Healthcare Research and Quality (AHRQ) R24HS022418
Grant Title	UT Southwestern Center of Patient-Centered Outcomes Research (PCOR)

Project Title	A comparative effectiveness randomized controlled trial of mailed outreach strategies to increase HCC screening among cirrhosis patients in a safety-net health system
Role	Project Leader (PI: Halm)
Award dates	9/30/13 – 9/29/2017

<u>Past</u>	Grantor: National Institute of Health (NIH) U54CA163308
Grant Title	Parkland-UT Southwestern PROSPR Center: colon cancer screening in a safety net
Project Title	Comparative Effectiveness of FIT, Colonoscopy, and Usual Care Screening Strategies for Colon Cancer Screening
Role	Project Leader (MPIs: Celette Skinner and Ethan Halm)
Award dates	9/23/11 – 5/31/2017

<u>Past</u>	Grantor: National Institute of Health (NIH) U24 CA171524
Project Title	Determinants of HCC Screening among Cirrhotic Patients in Integrated Health Care Systems
Role	Cancer Research Network (CRN) Scholar
Award dates	4/1/13 – 6/31/15

<u>Past</u>	Grantor: American Cancer Society and Simmons Cancer Center Institutional Grant
Project Title	Patient-level Determinants of HCC Screening among Cirrhotic Patients in a Safety-Net System
Role	Principal Investigator (PI: Singal)
Award dates	8/1/13 – 9/30/14

<u>Past</u>	Dedman Family Scholar in Clinical Care
Role	Scholar of Clinical Care
Award dates	7/1/10 – 6/30/14

<u>Past</u>	Grantor: American College of Gastroenterology
Project Title	Predictors of Screening Failure for Hepatocellular Carcinoma in a Safety Net Hospital
Role	Principal Investigator (PI: Singal)
Award dates	9/1/11 – 8/31/13

<u>Past</u>	Grantor: National Center for Research Resources (KL2 program)
Grant Title	North and Central Texas Clinical and Translational Science Initiative
Role	Clinical Scholar Trainee
Award dates	7/1/10 – 6/30/13

<u>Past</u>	Grantor: National Institutes of Health (T32 DK062708)
Grant Title	Training in Gastrointestinal Epidemiology
Role	Trainee

Award dates	7/1/2008 – 6/30/2010
-------------	----------------------

### **Teaching Activities**

<b>Year(s)</b>	<b>Activity</b>
<b><u>Medical and graduate school didactic and small group teaching</u></b>	
2011 – 2012	Board Review Q&A Sessions for Gastroenterology Fellows (monthly)
2014	Study Design for Summer Research Students (weekly for one month)
2016- present	Liver Masses Lecture, Integrative Medicine Gastroenterology and Nutrition
<b><u>Dissertation committees</u></b>	
2013	Melbourne University, PhD committee for thesis on Liver Disease and HCC (Anthony Rode)
2018	Texas A&M University School of Public Health, PhD committee for thesis on HCC (Debra Tan)
2020	Texas A&M University School of Public Health, PhD committee for thesis on costs of cancer care (Mohammad Karim)
2021	Aarhus University Health, PhD committee for thesis on HCC (Peter Jepsen)
<b><u>Qualifying examination committees</u></b>	
<i>None</i>	
<b><u>Committees concerned with medical and graduate student education</u></b>	
2011 – 2012	Poster Judge, Medical Student Research Forum (annually)
2012 – 2013	Co-Chair, Gastroenterology Fellowship Education Committee
2012 – 2017	Chair, Gastroenterology Fellowship Research Committee
<b><u>Graduate student rotations</u></b>	
2010 – present	Attending Liver Inpatient Service
2010 – present	Gastroenterology/Liver Fellows Clinic Attending
<b><u>Medical student rotations</u></b>	
<i>None</i>	
<b><u>Graduate student trainees</u></b>	
2013	Mechanisms of Disease Mentor (Hema Majunath)
<b><u>Postgraduate medical education (graduate &amp; continuing medical education)</u></b>	
2012 – 2020	Hepatology lectures to Gastroenterology fellows (1-2 lectures annually)
2012 – present	Hepatology lecture to Internal Medicine residents (one lecture annually)
2017 – present	Liver cancer lecture to oncology fellows (annually)
<b><u>Postdoctoral trainees</u></b>	
<i>None</i>	

### **Invited Lectures**

<b>Year(s)</b>	<b>Title</b>	<b>Location</b>
<b><u>International</u></b>		

September 2010	Surveillance ultrasound has a poor sensitivity for early stage HCC in American patients with cirrhosis	International Liver Cancer Association Annual Meeting, Montreal, Canada
September 2012	Detection of Hepatocellular Carcinoma at Advanced Stages Among Patients in the HALT-C Trial: Where did Surveillance Fail?	International Liver Cancer Association Annual Meeting, Berlin, Germany
September 2012	Should we use AFP for Surveillance of HCC?	International Liver Cancer Association Annual Meeting, Berlin, Germany
September 2013	Primary and Secondary Prevention of HCC	International Liver Cancer Association Annual Meeting, Washington DC, USA
September 2013	Machine Learning Algorithms Outperform Conventional Regression Models in Predicting Development of Hepatocellular Carcinoma	International Liver Cancer Association Annual Meeting, Washington DC, USA
February 2014	HCC Surveillance: Tests, Intervals, and Uptake	Canadian Association for the Study of the Liver, Toronto, Canada
September 2014	Surveillance for Hepatocellular Carcinoma Improves Early Detection, Curative Treatment, and Overall Survival in Patients with Cirrhosis	International Liver Cancer Association Annual Meeting, Kyoto, Japan
September 2014	Outcomes Following Downstaging of Hepatocellular Carcinoma for Liver Transplantation: A Meta Analysis	International Liver Cancer Association Annual Meeting, Kyoto, Japan
September 2014	The Influence of Hospital Volume on Outcome Measures in Hepatocellular Carcinoma	International Liver Cancer Association Annual Meeting, Kyoto, Japan
July 2015	HCC diagnosis, prognostic markers and treatment: New data and current practice in the USA	Chinese Society of Hepatology, Beijing, China
July 2015	HCC diagnosis, prognostic markers and treatment: New data and current practice in the USA	Chinese Society of Hepatology, Shanghai, China
September 2015	Hepatocellular Carcinoma Early Detection	International Liver Cancer Association Annual Meeting, Paris, France
September 2015	Patient Knowledge and Barriers for HCC Surveillance among Patients with Cirrhosis	International Liver Cancer Association Annual Meeting, Paris, France
February 2016	Should AFP be used with US for HCC Surveillance?	Canadian Association for the Study of the Liver, Toronto, Canada
September 2016	Randomized Trial of Mailed Outreach and Navigation to Improve Hepatocellular Carcinoma Screening Rates in Cirrhosis	International Liver Cancer Association Annual Meeting, Vancouver, Canada

May 2017	Hepatocellular Carcinoma: Best of AASLD, EASL, ALEH, and ASCO	Association Latino Americana Para El Estudio Del Hígado
September 2017	Precision Screening: Hope or Hype	International Liver Cancer Association Annual Meeting, Seoul, Korea
September 2017	Direct acting antiviral is associated with shorter time to HCC recurrence but not increased risk of recurrence	International Liver Cancer Association Annual Meeting, Seoul, Korea
September 2017	Randomized Clinical Trial of Mailed Outreach and Navigation to Increase HCC Surveillance in Patients with Cirrhosis	International Liver Cancer Association Annual Meeting, Seoul, Korea
April 2018	Perspectives of HCC Surveillance in the Western World	Asan Liver Center Symposium, Seoul, Korea
May 2018	Effectiveness of HCC Surveillance in Patients with Cirrhosis	Sun Yat-sen University 7 <sup>th</sup> affiliated hospital, Shenzhen China
July 2018	Unification 2018: A small step for AASLD, a giant leap for LI-RADS	LI-RADS Teach the Teacher Webinar
July 2018	2018 Update Hepatocellular Carcinoma: Diagnosis and Staging	Society of Interventional Oncology and the France Foundation Webinar
September 2018	Surveillance Imaging and AFP for Early Detection of HCC in Patients with Cirrhosis: A Meta-Analysis	International Liver Cancer Association Annual Meeting, London, UK
April 2019	Liver Cancer and NAFLD: Does the cancer risk justify surveillance	European Association for the Study of the Liver, Vienna Austria
March 2020	Barriers and Controversies in HCC	Canadian Liver Meeting, Montreal Canada
March 2020	Best of AASLD: Hepatitis C	Canadian Liver Meeting, Montreal Canada
March 2020	Treatment of HCC: Resection, Ablation, or Transplantation	University of Toronto, Toronto Canada
April 2020	Surveillance and management of early and intermediate HCC during the COVID pandemic	International Liver Cancer Association webinar
May 2020	A non-radiologist perspective on clinical applications of LI-RADS	Liver Imaging Online Course 2020
August 2020	Risk and Prevention of HCV-related HCC	Joint International Conference of Taiwan Liver Cancer Association and Taiwan Academy of Tumor Ablation, Taipei, Taiwan
August 2020	New Horizon of Immuno-Oncology Therapy for Hepatocellular Carcinoma	Liver Week 2020, Seoul, South Korea

September 2020	Patient-reported Barriers are Associated with HCC Surveillance Receipt in a Multi-Center Cohort of Patients with Cirrhosis	International Liver Cancer Association Annual Meeting (all virtual)
September 2020	Improved Sensitivity for Early-Stage Hepatocellular Carcinoma Detection with a Novel Blood-based Panel of Methylated DNA and Protein Markers	International Liver Cancer Association Annual Meeting (all virtual)
October 2020	Advances in Therapy for Advanced HCC	University of Toronto, Toronto, Canada
November 2020	HCC Surveillance in the 21 <sup>st</sup> Century: Pitfalls and Challenges	Japan Digestive Disease Week, Kobe, Japan
November 2020	Epidemiology Trends of HCC	Korea Digestive Disease Week, Seoul, South Korea
December 2020	Trends of HCV-related HCC in the United States	Taiwan Association for the Study of the Liver, Kaohsiung City, Taiwan
January 2021	Hot Topics at AASLD: Hepatocellular Carcinoma	Hot Topics at AASLD 2020 Conference, New Delhi, India
March 2021	Expert Perspectives on Colorectal and Hepatocellular Cancer Cases	Aga Khan University, Nairobi Kenya
June 2021	Systemic Therapy Should be Option of Choice for Intermediate Stage HCC	Singapore Hepatology Conference
June 2021	Surveillance in HCC Patients: Future Directions	HCC Symposium, University Hospital of Bern, Bern, Switzerland
<b><u>National</u></b>		
May 2010	Patient Involvement is Correlated with Higher HCC Surveillance in Patients with Cirrhosis	Digestive Disease Week, New Orleans, LA
November 2011	Process of Care Failure Rates for Hepatocellular Carcinoma Surveillance	American Association for the Study of Liver Disease, San Francisco, CA
May 2012	The Impact of HIV Serologic Status on Clinical Presentation, Treatment, and Survival in Patients with Hepatocellular Carcinoma	Digestive Disease Week, San Diego, CA
May 2013	Institution of a Multidisciplinary Clinic Reduces Therapeutic Delays for Patients with Hepatocellular Carcinoma	Digestive Disease Week, Orlando, FL
May 2013	Patient-level Determinants of Alpha Fetoprotein Elevation Among Patients with Cirrhosis	Digestive Disease Week, Orlando, FL
May 2013	Extrahepatic Metastases Plus Vascular Invasion in Patients with Hepatocellular Carcinoma Portends a Worse Prognosis than Extrahepatic Metastases or Vascular Invasion Alone	Digestive Disease Week, Orlando, FL

December 2013	HCC Surveillance: where should we be and how can we get there?	Baylor College of Medicine Houston, TX
May 2014	Primary Care Provider Knowledge Regarding Hepatocellular Carcinoma Surveillance In Patients with Cirrhosis	Digestive Disease Week, Chicago, IL
July 2014	Surveillance for and Diagnosis of Small Hepatocellular Carcinoma	AASLD Hepatobiliary Neoplasia SIG Webinar
July 2014	Recall Mechanisms for Indeterminate Liver Lesions	AASLD Hepatobiliary Neoplasia SIG Webinar
February 2015	HCC Surveillance in Patients with Cirrhosis: Narrowing the Gap Between Efficacy and Effectiveness	Mount Sinai Health System, New York, NY
April 2015	Hepatocellular Carcinoma Screening and Treatment	RUSH University, Chicago, IL
May 2015	Outreach invitations for FIT and colonoscopy improve colorectal cancer screening rates: Results of a randomized controlled trial in a safety net health system	Digestive Disease Week, Washington DC
November 2015	Models of Care for Hepatocellular Carcinoma	AASLD Post-graduate course San Francisco, CA
February 2016	Hepatocellular Carcinoma Screening in Patients with Cirrhosis	UC San Diego, San Diego, CA
March 2016	Guideline Debate about HCC Screening in Patients with Cirrhosis	American Society of Preventive Oncology, Columbus, OH
November 2016	Hepatocellular Carcinoma Surveillance After Hepatitis C Sustained Viral Response	AASLD Post-graduate course, Boston MA
August 2017	HCC Surveillance: Roadmap for Improving Value in Patients with Cirrhosis	Mount Sinai Health System, New York NY
October 2017	The HCC Care Continuum for Early Detection to Treatment	Loma Linda, Las Vegas NV
October 2017	Update on Surveillance and Diagnosis of Hepatocellular Carcinoma in Patients with Cirrhosis	American College of Gastroenterology, Orlando FL
October 2017	Hepatitis C Treatment and Risk of Recurrent Hepatocellular Carcinoma	American Association for the Study of Liver Diseases, Washington DC
October 2017	A New Era of Systemic Therapy in Patients with HCC	Rush University, Chicago IL
January 2018	HCC Surveillance: A Roadmap for Improving Value in Patients with Cirrhosis	Beth Israel, Boston MA
February 2018	Management of HCV-related Hepatocellular Carcinoma	Mount Sinai Institute for Advanced Medicine, HepCure webinar, New York NY

February 2018	HCC Surveillance: Pitfalls and the Path Forward	Banner University Annual Symposium, Phoenix AZ
May 2018	HCC Epidemiology and Surveillance	University of Chicago, Chicago IL
June 2018	Screening for Hepatocellular Carcinoma: How Can we Do Better?	Emory University, Atlanta, GA
August 2018	HCC Surveillance: A Blueprint for improving its effectiveness in the United States	Oregon Health & Sciences University, Portland OR
September 2018	Early Diagnosis of HCC: Where are we and where are we going?	Mercy Medical System, Baltimore MD
November 2018	Racial/Ethnic Disparities in Epidemiology and Screening for Liver Cancer	AACR Conference, New Orleans LA
November 2018	Optimizing Surveillance Programs for Hepatocellular Carcinoma	National Cancer Institute, Bethesda, MD
November 2018	Direct Acting Antiviral Therapy is Not Associated with Recurrence of HCC: A North American Cohort Study	American Association for the Study of Liver Diseases, San Francisco, CA
November 2018	HCC Surveillance: Gaps in Clinical Practice	University of North Carolina, Raleigh, NC
December 2018	Hepatocellular Carcinoma: New and Emerging Treatments	Southern California Society of Gastroenterology, Los Angeles, CA
January 2019	HCC Surveillance: Current status and what's on the horizon	University of Michigan, Ann Arbor MI
January 2019	Liver cancer: why we're losing the war (and how we can start winning)	University of Colorado, Denver CO
February 2019	Hepatocellular Carcinoma: Updates in Surveillance and Therapeutics	Banner University Annual Symposium, Phoenix AZ
March 2019	Hepatocellular Carcinoma: Screening and Treatment	GI and Liver Association of the Americas, Dallas TX
May 2019	Hepatocellular Carcinoma: Understanding How We Can Do Better	Northwestern University, Chicago IL
June 2019	Gastroenterology Fellowship Graduation Keynote: My Path to "Success"	University of Michigan, Ann Arbor MI
June 2019	Approach to Liver Lesions: Abnormal ultrasound, please evaluate	ACG Eastern Regional Postgraduate Course, Washington DC
June 2019	Hepatocellular Carcinoma: A Cancer on the Rise	Loyola University Internal Medicine Grand Rounds, Chicago IL
June 2019	Hepatocellular Carcinoma: Emerging Concepts in Early Detection	University of Tennessee Liver Transplant Conference, Memphis TN



September 2019	Epidemiology, Surveillance and Diagnosis of HCC	Houston Methodist Annual Conference, Houston TX
September 2019	Issues with surveillance in a NASH population	International Liver Cancer Association, Chicago IL
November 2019	Barriers, Controversies and Strategies for HCC Surveillance	American Association for the Study of Liver Diseases, Boston MA
November 2019	Financial Burden is Common in US Patients with Cirrhosis and Associated with Lower HCC Surveillance Receipt	American Association for the Study of Liver Diseases, Boston MA
November 2019	DAA Therapy is Associated with Improved Survival in Patients with a History of HCC: A Multicenter North American Cohort Study	American Association for the Study of Liver Diseases, Boston MA
November 2019	Thrombocytosis and Survival in Hepatocellular Carcinoma	American Association for the Study of Liver Diseases, Boston MA
December 2019	Advances in Hepatocellular Carcinoma Surveillance	University of North Carolina, Chapel Hill, NC
January 2020	HCC Surveillance: What's on the Horizon in 2020?	Cedars Sinai, Los Angeles CA
January 2020	NASH and HCC: Who needs to be in Surveillance?	ASCO-GI, San Francisco, CA
February 2020	Update on Hepatocellular Carcinoma	Banner University Annual Symposium, Phoenix AZ
February 2020	Multidisciplinary Care of Patients with HCC	HCC-TAG, Park City, UT
May 2020	Challenges in Management of HCC: Diagnosis and Treatment ( <i>canceled due to COVID</i> )	DDW post-graduate course, Chicago IL
August 2020	HCC and Post-Transplant Malignancy	AASLD Transplant Hepatology Board Review Course
October 2020	Cost-effectiveness of HCC surveillance strategies in patients with cirrhosis	Society of Advanced Body Imaging
October 2020	Multidisciplinary Tumor Board Featuring Hepatobiliary and Colorectal Cases	Society of Advanced Body Imaging
October 2020	HCC Surveillance: Potential Role of Biomarkers and Modeling	Early Detection Research Network (EDRN) Steering Committee Meeting
October 2020	Randomized Clinical Trial of Serum Biomarkers vs. Ultrasound for Early Detection of HCC	Early Detection Research Network (EDRN) Steering Committee Meeting
November 2020	Surveillance for hepatocellular carcinoma and cholangiocarcinoma in patients with liver disease	AASLD Annual Meeting Clinical Practice SIG
November 2020	Meet the Expert: Screening for Hepatocellular Carcinoma	AASLD Annual Meeting MTE session

December 2020	Project 2025: A Vision for the Oncology Hepatocellular Carcinoma – Changes in Treatment Paradigms	FDA Oncology Center of Excellence mini symposium
February 2021	Improving effectiveness of HCC Surveillance: Challenges and Potential Solutions	Columbia University, New York, NY
March 2021	Patient Journey: Early to Intermediate Stage HCC	HCC-TAG, Park City, UT
March 2021	Strategies to Optimize Delivery of HCC Screening in Patients with Cirrhosis	CTEU Seminar, Massachusetts General Hospital, Boston MA
April 2021	Recommendations to Optimize Surveillance of HCC	Chronic Liver Disease Foundation HCC Innovations webinar series
May 2021	HCC Surveillance in the 21 <sup>st</sup> Century: Controversies, Pitfalls, and Perspectives	USC Cancer Epidemiology Seminar, University of South California, Los Angeles, CA
June 2021	Guidelines Provide Accurate Direction for HCC Surveillance in HBV Patients	HBV-TAG, Virtual meeting
June 2021	LI-RADS: Is there a Clinical Need?	Society of Abdominal Radiology Webinar
<b><u>Regional/Local</u></b>		
September 2010	Liver Transplantation	UT Southwestern Nursing, Dallas TX
January 2011	Hepatocellular Carcinoma: Who is at Risk and What We Can Do	UT Southwestern APAMSA, Hepatitis Week, Dallas, TX
February 2011	Hepatocellular Carcinoma: An Update	What's New in Gastroenterology and Hepatology Annual Symposium, Dallas, TX
April 2011	HCC Risk in Chronic Liver Disease: Screening and Antiviral Therapies	UT Southwestern GI Cancer Symposium, Dallas, TX
February 2012	Hepatocellular Carcinoma and Viral Hepatitis	Texas College of Osteopathic Medicine APAMSA, Fort Worth, TX
February 2012	Complications of Cirrhosis: An Update	What's New in Gastroenterology and Hepatology Annual Symposium, Dallas, TX
February 2012	Surveillance for Hepatocellular Carcinoma: How Can We Do Better?	UT Southwestern Internal Medicine Grand Rounds, Dallas, TX
June 2012	Best of DDW: Non-Viral Liver Disease	Best of Digestive Disease Week, Dallas, TX

August 2012	Imaging Characteristics for Hepatocellular Carcinoma	UT Southwestern Department of Radiology, Dallas, TX
October 2012	Hepatocellular Carcinoma Surveillance: More Questions than Answers	Texas Health, Internal Medicine Grand Rounds, Dallas, TX
November 2012	Liver Disease and Transplantation	UT Southwestern Nursing, Dallas TX
February 2013	Surveillance for Hepatocellular Carcinoma: To Do or Not To Do?	Controversies in Gastroenterology and Hepatology Annual Symposium, Dallas, TX
February 2013	Primary Liver Cancer	New York Life Insurance Company, Dallas, TX
February 2015	Therapies for Hepatocellular Carcinoma	Update in Liver Diseases Symposium, Dallas, TX
March 2015	Hepatocellular Carcinoma: Early Detection to Diagnosis to Treatment	Medical Center of Lewisville Grand Rounds, Lewisville, TX
September 2015	Texas HepCa: Increasing Hepatocellular Carcinoma Awareness	Texas Medical Association Austin, TX
April 2016	Hepatocellular Carcinoma: A deadly complication of viral hepatitis	UT Southwestern APAMSA, Hepatitis Week, Dallas, TX
April 2016	Hepatocellular Carcinoma Screening: Changes in the Paradigm	UT Southwestern GI Cancer Symposium, Dallas, TX
May 2016	Texas HepCa: Increasing Hepatocellular Carcinoma Awareness	Texas Medical Association Austin, TX
May 2016	Hepatocellular Carcinoma	Update in Liver Diseases Symposium, Dallas, TX
May 2017	Overview of Viral Hepatitis and Link to Hepatocellular Carcinoma	DFW Metroplex Summit, Dallas TX
May 2017	Hepatocellular Carcinoma: A deadly complication of Viral Hepatitis	American Liver Foundation, Dallas TX
December 2017	Hepatocellular Carcinoma: An Update	Update in Liver Diseases Symposium, Dallas, TX
December 2017	Hepatocellular Carcinoma: Prognosis and Treatment	Division of Medical Oncology Conference, Dallas, TX
January 2018	Turning the Tide on the Liver Cancer Epidemic in Texas	UT Southwestern Internal Medicine Grand Rounds, Dallas TX
February 2018	Hepatitis C Therapy and HCC: Friend or Foe?	Baylor Scott & White, Dallas TX
May 2018	Hepatocellular Carcinoma: Primary Liver Cancer in Texas and the US	American Liver Foundation, Dallas TX

October 2018	Hepatocellular Carcinoma Surveillance in 2018: Who, Why, and How	UT Southwestern Internal Medicine Noon Conference, Dallas TX
November 2018	UT Southwestern and Parkland: Fight Against the HCC Epidemic in Texas	UT Southwestern-Parkland Combined Cancer Center Committee Meeting
December 2018	HCC: What do I really need to know?	UT Southwestern Internal Medicine Noon Conference, Dallas TX
January 2019	Liver masses	MSTP Grand Rounds, Dallas TX
February 2019	Hepatocellular Carcinoma: Prognosis and Treatment	Division of Medical Oncology Conference, Dallas, TX
April 2019	HCC: Where does research play a role?	Clinical Research Office Seminar Series, Dallas TX
October 2019	National Liver Conference HCC Panel	National Liver Conference, San Antonio, TX
October 2020	Effectiveness of HCC Surveillance	Texas Collaborative Center for HCC (TeCH) Annual Symposium, Houston TX
April 2021	Update on Hepatocellular Carcinoma	UT Southwestern Update in Internal Medicine CME Conference, Dallas TX
April 2021	DFW COVID-19 Prevalence Study	COVID-19 Symposium, Dallas TX

## **Bibliography**

### **Peer-Reviewed Publications**

#### **Original Research Articles** (\* denotes co-first or co-senior author publications)

1. Chen PJ, **Singal A**, Kimble J, Ellis, RE. A Novel Member of the Tob Family of Proteins Controls Sexual Fate in *Caenorhabditis elegans* Germ Cells. *Developmental Biology* 2000; 217(1): 77-90.
2. **Singal A**, Volk ML, Waljee AK, Salgia R, Higgins P, Rogers M, Marrero JA. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. *Alimentary Pharmacology and Therapeutics* 2009; 30(1): 37-47.
3. **Singal AG**, Rakoski MO, Salgia R, Pelletier S, Welling TH, Fontana RJ, Lok AS, Marrero JA. Clinical Presentation and Prognostic Factors for Intrahepatic and Extrahepatic Cholangiocarcinoma in a Tertiary Care Centre. *Alimentary Pharmacology and Therapeutics* 2010; 31(6): 625-33.
4. **Singal AG\***, Volk ML\*, Jensen D, Di Bisceglie A, Schoenfeld PS. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. *Clinical Gastroenterology and Hepatology* 2010; 8(3): 280-288.

5. **Singal AG**, Waljee AK, Shiffman M, Bacon BR, Schoenfeld PS. Meta-analysis: re-treatment of genotype 1 hepatitis C nonresponders and relapsers after failing interferon and ribavirin combination therapy. *Alimentary Pharmacology and Therapeutics* 2010; 32(8): 969-983.
6. Rakoski MO, **Singal AG**, Rogers M, Conjeevaram H. Meta-Analysis: Insulin Sensitizers for the Treatment of Nonalcoholic Steatohepatitis. *Alimentary Pharmacology and Therapeutics* 2010; 32(10): 1211-1221
7. Jafri M, **Singal AG**, Kaul D, Fontana RJ. Detection and Management of Latent Tuberculosis in Liver Transplant Patients. *Liver Transplantation* 2011; 17(3): 306-314.
8. **Singal AG**, Thomassen LV, Gretch DR, Shuhart MC. Use of the AST to Platelet Ratio Index (APRI) in HCV/HIV co-infected Patients. *Alimentary Pharmacology and Therapeutics* 2011; 33(5): 566-577.
9. Jorgensen JE, Waljee AK, Volk ML, Sonnenday CJ, Elta GH, Al-Hawary MM, **Singal AG**, Taylor JR, Elmunzer BJ. Is MRCP equivalent to ERCP for diagnosing biliary obstruction in orthotopic liver transplant recipients? A meta-analysis. *GIE: Gastrointestinal Endoscopy* 2011; 73(5): 955-62.
10. **Singal AG**, Volk ML, Rakoski MO, Fu S, Su G, McCurdy H, Marrero JA. Patient involvement in healthcare is associated with higher rates of surveillance for hepatocellular carcinoma. *J Clinical Gastroenterology* 2011; 45(8): 727-732.
11. Lewis JJ, Rubenstein JH, **Singal AG**, Piraka CR. Factors associated with esophageal stricture development following endoscopic mucosal resection for neoplastic Barrett's esophagus. *Gastrointestinal Endoscopy* 2011; 74(4): 753-760.
12. **Singal AG**, Chan V, Getachew Y, Guerrero R, Reisch JS, Cuthbert JA. Predictors of Liver Transplant Eligibility for Patients with Hepatocellular Carcinoma in a Safety Net Hospital. *Digestive Diseases and Sciences* 2012; 57(2): 580-586.
13. **Singal AG**, Yopp A, Skinner CS, Packer M, Lee WM, Tiro JA. Utilization of Hepatocellular Carcinoma Surveillance Among American Patients: A Systematic Review. *J General Internal Medicine* 2012; 27(7): 861-867.
14. **Singal AG**, Conjeevaram H, Fu S, Volk ML, Fontana RJ, Askari F, Su GL, Lok AS, Marrero JA. Effectiveness of Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis. *Cancer Epidemiology Biomarkers & Prevention* 2012; 21(5): 793-9.
15. Cohen S, Saxena A, Waljee A, Piraka C, Purdy J, Appelman H, McKenna B, Elmunzer BJ, **Singal AG**. Lymphocytic Esophagitis: A Diagnosis of Increasing Frequency. *J Clinical Gastroenterology* 2012; 46(10): 828-832.
16. **Singal AG**, Yopp A, Gupta S, Skinner CS, Halm EA, Okolo E, Nehra M, Lee WM, Marrero JA, Tiro JA. Failure Rates in the Hepatocellular Carcinoma Surveillance Process. *Cancer Prevention Research* 2012; 5(9): 1124-1130.
17. Yopp AC, Subramanian M, Jain MK, Mansour JC, Schwarz RE, Balch GC, **Singal AG**. Presentation, Treatment, and Clinical Outcomes of Patients with Hepatocellular Carcinoma, with and without Human Immunodeficiency Virus Infection. *Clinical Gastroenterology and Hepatology* 2012; 10(11): 1284 – 1290.
18. Elmunzer BJ, Debenedet A, Volk M, Sonnenday CJ, Waljee AK, Fontana F, Elta G, Oza A, **Singal AG**, Englesbe M, Scheiman J. Clinical Yield of diagnostic ERCP in orthotopic liver

- transplant recipients with suspected biliary complications. *Liver Transplantation* 2012; 18(12): 1479-84.
19. Nehra M, Ma Y, Clark C, Amarasingham R, Rockey DC, **Singal AG**. Use of Administrative Claims Data for Identifying Patients with Cirrhosis. *J. Clinical Gastroenterology* 2013; 47(5): e50-4.
  20. **Singal AG**, Nehra M, Adams-Huet B, Yopp AC, Tiro JA, Marrero JA, Lok AS, Lee WM. Detection of Hepatocellular Carcinoma at Advanced Stages among Patients in the HALT-C Trial: Where Did Surveillance Fail? *American J. Gastroenterology* 2013; 108(3): 425-32.
  21. Urrunaga NH, **Singal AG**, Cuthbert JC, Rockey DC. Hemorrhagic Ascites: Clinical Presentation and Outcomes of Patients with Cirrhosis. *J. Hepatology* 2013; 58(6): 1113-8.
  22. Lee E, Edward S, **Singal AG**, Lavieri MS, Volk ML. Improving Screening for Hepatocellular Carcinoma by Incorporating the Pattern of Alpha-fetoprotein over Time. *Clinical Gastroenterology & Hepatology* 2013; 11(4): 437-440.
  23. Waljee AK, Mukherjee A, **Singal AG**, Zhang Y, Warren J, Balis U, Marrero JA, Zhu J, Higgins PDR. Comparison of Modern Imputation Methods for Missing Laboratory Data in Medicine. *BMJ Open* 2013; 3(8): e002847
  24. Chen E, Lee WM, Hynan L, **Singal AG**. A Survey of Hepatitis C Treatment Clinical Practice Patterns using the Newly Approved Protease Inhibitors. *J. Clinical Gastroenterology* 2013; 47(9): 800-6.
  25. Tan D, Yopp AC, Beg MS, Gopal P, **Singal AG**. Meta-analysis: Underutilisation and Disparities of Treatment among Patients with Hepatocellular Carcinoma in the United States. *Alimentary Pharmacology & Therapeutics* 2013; 38(7): 703-12.
  26. **Singal AG**, Dharia T, Malet PF, Alqahtai S, Zhang S, Cuthbert JC. Long-term Benefit of Hepatitis C Therapy in a Safety Net Hospital System: A Cross-Sectional Study with median 5 year follow-up. *BMJ Open* 3 (9): e003231
  27. **Singal AG**, Rahimi RS, Clark C, Ma Y, Cuthbert JC, Rockey DC, Amarasingham R. An Automated Model Using Electronic Medical Record Data to Identify Patients with Cirrhosis at High Risk for Readmission. *Clinical Gastroenterology and Hepatology* 2013; 11(10): 1335-41.
  28. **Singal AG**, Waljee AK, Patel N, Tiro JA, Marrero JA, Yopp AC. Therapeutic Delays Lead to Worse Survival among Patients with Hepatocellular Carcinoma. *J National Comprehensive Cancer Network* 2013; 11(9): 1101-1108.
  29. **Singal AG**, Mukherjee A, Elmunzer BJ, Higgins PDR, Lok AS, Zhu J, Marrero JA, Waljee AK. Machine Learning Algorithms Outperform Conventional Regression Models in Predicting Development of Hepatocellular Carcinoma. *American J Gastroenterology* 2013; 108: 172 –1730.
  30. **Singal AG**, Manjunath, H, Yopp AC, Marrero JA, Gopal P, Waljee AK. The effect of PNPLA3 on Fibrosis Progression and Development of Hepatocellular Carcinoma: A meta-analysis. *American J Gastroenterology* 2014; 109: 325-334.
  31. Yopp AC, Mansour J, Beg MS, Arenas J, Trimmer C, Reddick M, Pedrosa I, Khatri G, Yakoo T, Meyers JJ, Shaw J, Marrero JA, **Singal AG**. Establishment of a Multidisciplinary Hepatocellular Carcinoma Clinic is Associated with Improved Clinical Outcome. *Annals of Surgical Oncology* 2014; 21: 1287-95.

32. Stidham RW, Lee T, Higgins PDR, Deshpande A, Sussman DA, **Singal AG**, Elmunzer BJ, Sanai S, Vijan S, Waljee AK. Systematic review with network meta-analysis: the efficacy of anti-tumor necrosis factor-alpha agents for the treatment of ulcerative colitis. *Alimentary Pharmacology & Therapeutics* 2014; 39: 660-671.
33. **Singal AG**, Marrero JA, Yopp AC. Screening Process Failures for Hepatocellular Carcinoma. *J National Comprehensive Cancer Network* 2014; 12(3): 375-82.
34. **Singal AG**, Pillai A, Tiro JA. Early Detection, Curative Treatment, and Survival Rates for HCC Surveillance in Patients with Cirrhosis: A meta-analysis. *PLOS Medicine* 2014; 11(4): e1001624.
35. Salgia R, **Singal AG**, Fu S, Pelletier, S, Marrero JA. Improved Post-Transplant Survival in the United States for Patients with Cholangiocarcinoma after 2000. *Digestive Diseases Sciences* 2014; 59(5): 1048-54.
36. Gopal P, Yopp AC, Waljee AK, Chiang J, Nehra, M, Kandunoori P, **Singal AG**. Factors that Affect the Accuracy of Alpha Fetoprotein Test in Detection of Hepatocellular Carcinoma in Patients with Cirrhosis. *Clinical Gastroenterology and Hepatology* 2014; 12(5): 870-7.
37. Stidham RW, Lee T, Higgins PDR, Deshpande A, Sussman DA, **Singal AG**, Elmunzer BJ, Sanai S, Vijan S, Waljee AK. Systematic review with network meta-analysis: the efficacy of anti-tumor necrosis factor-alpha agents for the treatment of Crohn's disease. *Alimentary Pharmacology & Therapeutics* 2014; 39(12): 1349-62.
38. Rahimi RS, **Singal AG**, Cuthbert JA, Rockey DC. Lactulose vs. Polyethylene Glycol 3350-Electrolyte Solution for Treatment of Overt Hepatic Encephalopathy: The HELP Randomized Clinical Trial. *JAMA Internal Medicine* 2014; 174(11): 1727-33.
39. **Singal AG**, Li X, Tiro JA, Kandunoori P, Huet B, Nehra M, Yopp AC. Racial, Social, and Clinical Determinants of Hepatocellular Carcinoma Surveillance. *American Journal of Medicine* 2015; 128(1): 90e1 – 90e7.
40. Elmunzer, BJ, **Singal AG**, Sussman JB, Deshpande A, Sussman D, Conte M, Dwamena B, Rogers M, Schoenfeld PS, Inadomi JM, Saini SD, Waljee AK. Comparing the Effectiveness of Competing Tests for Colorectal Cancer Screening: A Network Meta-Analysis. *Gastrointestinal Endoscopy* 2015; 81(3): 700-9
41. Dalton-Fitzgerald E, Tiro J, Kandunoori P, Halm E, Yopp A, **Singal AG**. Practice Patterns and Attitudes of Primary Care Providers and Barriers to Surveillance of Hepatocellular Carcinoma in Patients with Cirrhosis. *Clinical Gastroenterology and Hepatology* 2015;13(4):791-8.
42. Patel N, Yopp AC\*, **Singal AG\***. Diagnostic Delays are Common among Patients with Hepatocellular Carcinoma. *J National Comprehensive Cancer Network* 2015; 13(5): 543-9.
43. Zacharias T, Wang W, Dao D, Wojciechowski H, Lee WM, Do S, **Singal AG**. HBV Outreach Programs Significantly Increase Knowledge and Vaccination Rates among Asian Pacific Islanders. *J Community Health* 2015; 40(4): 619-24.
44. Martin J, Khatri G, Gopal P, **Singal AG**. Accuracy of Ultrasound and Non-invasive Serum Markers of Fibrosis to Identify Patients with Cirrhosis. *Digestive Diseases Sciences* 2015; 60(6): 1841-7.
45. Tujios SR, Rahnema-Moghadam S, Elmunzer BJ, Kwon R, **Singal AG**, Anderson MA, Wamsteker E, Taylor J, Scheiman J, Elta G, Piraka C, Fontana RJ. Transpapillary Gallbladder

- Stents can stabilize or improve decompensated cirrhotics awaiting liver transplantation. *J Clinical Gastroenterology* 2015; 49(9): 771-7.
46. Parikh N, Waljee A, **Singal AG**. Downstaging Hepatocellular Carcinoma: A Systematic Review and Pooled Analysis. *Liver Transplantation* 2015; 21(9): 1142-52.
  47. Meier A, Yopp A, Kandunoori P, Mok H, Tiro J, **Singal AG**. Role Functioning is Associated with Survival in Patients with Hepatocellular Carcinoma. *Quality of Life Research* 2015; 24(7): 1669-75.
  48. Patel N, Tong L, Ahn C, **Singal AG**, Gupta S. Post-polypectomy guideline adherence: Importance of Belief in Guidelines, Not Guideline Knowledge or Fear of Missed Cancer. *Digestive Diseases Sciences* 2015; 60(10): 2937-45.
  49. Kahn B, Freeland Z, Gopal P, Agrawal D, Mayorga CA, Mithani R, Skinner CS, Halm EA, **Singal AG**. Predictors of Guideline Concordance for Surveillance Colonoscopy Recommendations among Patients in an Academic Safety-Net Health System. *Cancer Control & Control* 2015; 26(11): 1653-60.
  50. Robbins R, Tian C, **Singal AG**, Agrawal D. Peri-procedural aspirin management during colonoscopy – a survey of practice patterns in the United States. *Gastrointestinal Endoscopy* 2015; 82(5): 895-900.
  51. Yopp AC, Mokdad A, Zhu H, Mansour JC, Balch GC, Choti MA, **Singal AG**. Infiltrative Hepatocellular Carcinoma: Natural History and Comparison with Multifocal, Nodular Hepatocellular Carcinoma. *Annals Surgical Oncology* 2015; 22(S3): 1075-82.
  52. Patel J, Yopp A, Waljee A, **Singal AG**. Development and Internal Validation of a Model for Early Detection of Hepatocellular Carcinoma in Patients with Cirrhosis. *J Clinical Gastro* 2016; 50(2): 175-9.
  53. Mokdad AE, Browning T, Mansour JC, Balch GC, Choti MA, **Singal AG**, Yopp AC,. Implementation of a voice messaging system is associated with improved time-to-treatment and overall survival in patients with hepatocellular carcinoma. *J National Comprehensive Cancer Network* 2016; 14(1): 38-46.
  54. Ali M, Gopal P, Yopp A, Beg MS, Zhu H, Lee W, **Singal AG**. A Variant in PNPLA3 Associated with Fibrosis Progression but not Hepatocellular Carcinoma in Patients with Hepatitis C Virus Infection. *Clinical Gastroenterology Hepatology* 2016; 14(2): 295-300.
  55. Skinner CS, Gupta S, Halm E, Wright S, McCallister K, Bishop W, Santini N, Mayorga C, Agrawal D, Moran B, Sanders JM, **Singal AG**. Development of the Parkland-UT Southwestern Colonoscopy Pathology Reporting System (CoRS) for evidence-based colon cancer surveillance recommendations. *JAMIA* 2016; 23(2): 402-6.
  56. Chubak J, Garcia M, Burnett-Hartman A, Zheng Y, Corley DA, Halm EA, **Singal AG**, Klabunde CN, Doubeni CA, Kamineni A, Levin TR, Schottinger JE, Green BB, Quinn VP, Rutter CM. Time to colonoscopy after positive fecal blood test in four US healthcare systems. *Cancer Epi Biomarkers Prevention* 2016; 25(2): 344-50.
  57. Wang M, Devarajan K, **Singal AG**, Marrero J, Feng Z, Rinaudo J, Srivastava S, Evans A, Hann H, Lai Y, Yang H, Block T, Mehta A. The Doylestown Algorithm – a test to improve the performance of AFP in the detection of hepatocellular carcinoma. *Cancer Prevention Research* 2016; 9(2): 172-9.



58. Agrawal D, Elsbernd B, **Singal AG**, Rockey D. Gastric Residual Volumes are Trivial Soon After Split Dose Polyethylene Glycol Bowel Preparation. *Gastrointestinal Endoscopy* 2016; 83(3): 574-80.
59. **Singal AG**, Gupta S, Tiro, JA, Skinner CS, McCallister K, Sanders JM, Bishop WP, Agrawal D, Mayorga C, Ahn C, Loewen A, Santini N, Halm EA. Outreach invitations for FIT and colonoscopy improve colorectal cancer screening rates: A randomized controlled trial in a safety net health system. *Cancer* 2016; 122(3): 456-63.
60. **Singal AG**, Zhang P, Waljee AK, Ananthkrishnan L, Parikh ND, Sharma P, Barman P, Krishnamurthy V, Wang L, Wang S, Su G. Body composition features predict overall survival in patients with hepatocellular carcinoma. *Clinical Translational Gastroenterology* 2016; 7: e172.
61. Mokdad A, Zhu H, Marrero JA, Mansour JC, Yopp AC\*, **Singal AG\***. Hospital Volume and Survival after Hepatocellular Carcinoma Diagnosis. *Am J Gastroenterology* 2016; 111(7): 967-75.
62. Parikh ND, Marshall VD, **Singal AG**, Nathan H, Lok AS, Balkrishnan R, Shahinian V. Survival and Cost-Effectiveness of Sorafenib Therapy in Advanced Hepatocellular Carcinoma: An analysis of the SEER-Medicare Database *Hepatology* 2017; 56(1): 122-33.
63. Martin J, Halm EA, Tiro JA, Merchant Z, Balasubramanian B, McCalliser K, Sanders JM, Ahn C, Bishop WP, **Singal AG**. Reasons for Lack of Diagnostic Colonoscopy after Positive FIT in a Safety-Net Health System. *Am J Medicine* 2017; 130(1): 93.e1-93.e7
64. Rich N, Tanriover B, **Singal AG**, Marrero JA. Outcomes of Simultaneous Liver Kidney Transplantation in Patients with Hepatocellular Carcinoma. *Transplantation* 2017; 10(1): e12-e19
65. Simmons O, Fetzer DT, Yokoo T, Marrero JA, Yopp A, Kono Y, Parikh N, Browning T, **Singal AG**. Predictors of Adequate Ultrasound Quality for HCC Surveillance in Patients with Cirrhosis. *Alimentary Pharmacology and Therapeutics* 2017; 45(1): 169-77.
66. Turner BJ, Liang Y, **Singal AG**. FIB-4 and Imaging for Measuring Fibrosis in Hepatitis C. *Eur J Gastro Hep* 2017; 29(2): 192-8.
67. Mokdad A, **Singal AG**, Marrero J, Zhu H, Yopp AC. Vascular Invasion and Metastases is Predictive of Outcome in Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma. *J National Comprehensive Cancer Network* 2017; 15(2): 197-204.
68. Farvardin S\*, Patel J\*, Khambaty M, Yerokun O, Mok H, Tiro JA, Yopp AC, Parikh ND, Marrero JA, **Singal AG**. Patient-Reported Barriers are Associated with Lower HCC Surveillance Rates in Patients with Cirrhosis. *Hepatology* 2017; 65(3): 875-84.
69. **Singal AG**, Tiro JA, Marrero JA, McCallister K, Mejias C, Sanders J, Bishop WP, Santini NO, Halm EA. Mailed Outreach Program Increases Ultrasound Screening of Patients with Cirrhosis for Hepatocellular Carcinoma. *Gastroenterology* 2017; 152(3): 608-15.
70. Reis S, Grzybowski R, Fisher S, Ball C, Sutphin P, **Singal AG**, Yopp A, Kalva SP. Tumor enhancement and heterogeneity are associated with treatment response to drug-eluting bead chemoembolization for hepatocellular carcinoma. *J Computer Assisted Tomography* 2017; 41(2): 289-93.
71. Atiq O, Tiro J, Yopp AC, Muffler A, Marrero JA, Parikh ND, Murphy C, McCallister K, **Singal AG**. An Assessment of Benefits and Harms of Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis. *Hepatology* 2017; 65(4): 1196-1205.

72. **Singal AG**, Tiro, J, Li X, Adams-Huet B, Chubak J. Hepatocellular Carcinoma Surveillance among Patients with Cirrhosis in a Population Based Integrated Healthcare Delivery System. *J Clin Gastro* 2017; 51(7): 650-5.
73. Naveed M, Clary M, Ahn C, Kubiliun N, Agrawal D, Cryer B, Murphy C, **Singal AG**. Accuracy of Referring Provider and Endoscopist Impression of Colonoscopy Indication. *J National Comprehensive Cancer Network* 2017; 15(7): 920-5.
74. Goosens N, **Singal AG**, King L, Andersson KL, Fuchs B, Besa-Correa C, Taouli B, Chung R, Hoshida Y. Cost-effectiveness of risk score-stratified hepatocellular carcinoma screening in patients with cirrhosis. *Clinical Translational Gastroenterology* 2017; 8(6): e101.
75. **Singal AG**, Mittal S, Yerokun OA, Ahn C, Marrero J, Yopp A, Parikh ND, Scaglione SJ. Hepatocellular Carcinoma Screening Associated with Early Tumor Detection and Improved Survival among Patients with Hepatocellular Carcinoma in the United States. *Am J Medicine* 2017; 130; 9: 1099-1106.e1
76. Yang JD, Dai J, **Singal AG**, Gopal P, Addissie B, Nguyen M, Befeler A, Reddy R, Schwartz M, Harnois D, Yamada H, Gores G, Feng Z, Marrero JA, Roberts LR. Improved Performance of Serum Alpha-Fetoprotein for Hepatocellular Carcinoma Diagnosis in HCV Cirrhosis with Normal Alanine Transaminase. *Cancer Epi Biomarkers Prevention* 2017; 26(7): 1085-92.
77. Wang M, Sanda M, Comunale MA, Harrera H, Swindell C, Kono Y, **Singal AG**, Marrero, J, Block T, Goldman R, Mehta, A. Changes in the glycosylation of kininogen and the development of a kininogen-based algorithm for the early detection of HCC. *Cancer Epi Biomarkers Prevention* 2017; 26(5): 795-803.
78. Parikh ND, **Singal AG**, Hutton DW. Cost-effectiveness of regorafenib as a second line therapy for patients with advanced hepatocellular carcinoma. *Cancer* 2017; 123(19): 3725-31.
79. **Singal AG**, Gupta S, Skinner CS, Ahn C, Santini NO, Agrawal D, Mayorga CA, Murphy C, Tiro JA, McCallister K, Sander JM, Bishop WP, Loewen AC, Halm EA. Effect of colonoscopy outreach versus fecal immunochemical test outreach on colorectal cancer screening completion: A randomized clinical trial. *JAMA* 2017; 318(9): 806-15.
80. Skinner CS, Ahn C, Halm, EA, Bishop WP, McCallister K, Sanders J, Farrell D, Santini N, **Singal AG**. Recommendation of colorectal cancer testing among primary care patients younger than 50 with elevated risk. *Preventive Medicine* 2017; 102: 20-23.
81. Yokoo T, Patel A, Lev-Cohain N, **Singal AG**, Yopp A, Pedrosa I. Extra-hepatic Metastasis Risk of Hepatocellular Carcinoma based on Alpha Fetoprotein and Tumor Staging Parameters at Cross-Sectional Imaging. *Cancer Management and Research* 2017; 9: 503-11.
82. Sun X, Wang SC, Luo X, Jia Y, Li L, Gopal P, Zhu M, Wei Y, Nassour I, Chuang JC, Maples T, Celen C, Nguyen L, Wu L, Fu S, Li W, Hui L, Tian F, Ji Y, Zhang S, Sorouri M, Hwang TH, Letzig L, James L, Wang Z, Yopp A, **Singal AG**, Zhu H. Arid1a has dose-dependent oncogenic and tumor suppressive roles in liver cancer. *Cancer Cell* 2017; 32(5): 574-89.
83. Yek C, de la Flor C, Marshall J, Zoellner C, Thompson G, Quirk L, Mayorga C, Turner B, Jain M, **Singal AG**. Effectiveness of direct-acting antiviral therapy for hepatitis C in difficult-to-treat patients in a safety-net health system: a retrospective cohort study. *BMC Medicine* 2017; 15(1): 204.

84. Waljee AK, Rogers M, Lin P, **Singal AG**, Stein JD, Marks RM, Ayanian JZ, Nallamotheu BK. Short-term use of oral corticosteroids and related harms among adults in the United States: population based cohort study. *BMJ* 2017; 357: j1415
85. Parikh ND, Zhang P, **Singal AG**, Derstine B, Krishnamurthy V, Barmna P, Waljee AK, Su GL. Body Composition predicts survival in patient with hepatocellular carcinoma treated with transarterial chemoembolization. *Cancer Research and Treatment* 2018; 50(2): 530-7.
86. Mokdad A, Murphy C, Pruitt S, Mansour JC, Marrero JA, Yopp AC\*, **Singal AG\***. Effect of Hospital Safety-Net Designation on Treatment Use and Survival in Hepatocellular Carcinoma. *Cancer* 2018; 124(4): 743-51.
87. Parikh ND, Scaglione S, Li Y, Powell C, Yerokun O, Devlin P, Caines A, Mittal S, **Singal AG**. A comparison of staging systems for hepatocellular carcinoma in a multicenter US cohort. *Clinical Gastroenterology Hepatology* 2018; 16(5): 781-2.
88. Rich NE, Oji S, Mufti A, Browning JD, Parikh ND, Odewole M, Mayo H, **Singal AG**. Racial and ethnic disparities in nonalcoholic fatty liver disease prevalence, severity, and outcomes in the United States: A meta-analysis. *Clinical Gastroenterology Hepatology* 2018; 16(2): 198-210
89. Tzartzeva K\*, Obi J\*, Rich NE, Parikh ND, Marrero JA, Yopp A, Waljee A, **Singal AG**. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in cirrhosis: A meta-analysis. *Gastroenterology* 2018; 154(6): 1706-18.e1
90. **Singal AG**, Corley D, Kamineni A, Garcia M, Zheng Y, Doria-Rose P, Quinn V, Jensen C, Chubak J, Tiro J, Doubeni C, Ghai N, Skinner CS, Wernli K, Halm EA. Patterns and Predictors of Repeat Fecal Immunochemical Test Screening in Four Large Health Systems in the United States. *Am J Gastro* 2018; 113(5): 746-54.
91. Saraiya N, Yopp AC, Rich NE, Parikh ND, **Singal AG**. Systematic review with meta-analysis: recurrence of hepatocellular carcinoma following direct acting antiviral therapy. *Alimentary Pharmacology and Therapeutics* 2018; 48(2): 127-37.
92. Murphy CC, Sigel BM, Yang E, Skinner CS, Halm EA, Gupta S, Sanders JM, McCallister K, **Singal AG**. Adherence to colorectal cancer screening as measured by proportion of time covered. *GIE* 2018; 88(2): 323-331.e2
93. Bangru S, Pedersen M, **Singal AG**, Mufti A. Survey of Liver Transplantation Practices for Severe Acute Alcoholic Hepatitis. *Liver Transplantation* 2018; 24(10): 1357-62.
94. Wang M, Shen J, Herrera H, **Singal AG**, Swindell C, Renquan L, Mehta A. Biomarker analysis of fucosylated kininogen through depletion of lectin reactive heterophilic antibodies in hepatocellular carcinoma. *J Immunol Methods* 2018; 462: 462-64.
95. Parikh ND, Marshall VD, Green M, Razumilava N, Owen D, **Singal AG**, Feng M. Effectiveness and Cost of Radiofrequency Ablation and Stereotactic Body Radiotherapy for Treatment of Early Stage Hepatocellular Carcinoma: An Analysis of SEER-Medicare *Journal of Medical Imaging and Radiation Oncology* 2018; 62(5): 673-681.
96. Magrath M\*, Yang E\*, Murphy C, Halm EA, Ahn C, Gopal P, Mayorga C, Agrawal D, Borton E, Skinner CSS, **Singal AG**. Impact of a clinical decision support system on guideline-adherence of surveillance recommendations for colonoscopy after polypectomy. *J National Comprehensive Cancer Network* 2018; 16(11): 1321-1328.

97. Murphy CC, **Singal AG**, Baron JA, Sandler RS. Decrease in increase of young-onset colorectal cancer before recent increase. *Gastroenterology* 2018; 155(6): 1716-1719.e4
98. Zhang S, Nguyen LH, Zhou K, Tu HC, Sehgal A, Nassour I, Li L, Gopal P, Goodman J, **Singal AG**, Yopp A, Zhang Y, Siewart DJ, Zhu H. Knockdown of Anillin Actin Binding Protein Blocks Cytokinesis in Hepatocytes and Reduces Liver Tumor Development in Mice without Affecting Regeneration. *Gastroenterology* 2018; 154(5): 1421-1434.
99. Garcia S, Pruitt SL, **Singal AG**, Murphy C. Colorectal cancer incidence among Hispanics and non-Hispanic whites in the National Program of Cancer Registries. *Cancer Causes and Control* 2018; 29(11): 1039-1046.
100. **Singal AG**, Tiro JA, Murphy CC, Marrero JA, McCallister K, Fullington H, Meijas C, Waljee AK, Bishop W, Santini N, Halm EA. Mailed Outreach Invitations Significantly Improve HCC Surveillance Rates in Patients with Cirrhosis: A Randomized Clinical Trial. *Hepatology* 2019; 69(1): 121-30.
101. Rich NE, Hester C, Odewole M, Murphy C, Parikh ND, Marrero JA, Yopp AC\*, **Singal AG\***. Racial and Ethnic Differences in Hepatocellular Carcinoma Presentation and Outcomes. *Clinical Gastroenterology Hepatology* 2019; 17(3): 551-559
102. Simmons OL, Feng Y, Parikh ND\*, **Singal AG\***. Primary Care Provider Practice Patterns and Barriers to Hepatocellular Carcinoma Surveillance. *Clinical Gastroenterology Hepatology* 2019; 17(4): 766-73.
103. Chubak J, McLerran D, Zheng Y, **Singal AG**, Corley DA, Doria-Rose P, Doubeni C, Kamineni A, Haas J, Halm EA, Skinner CS, Zauber AG, Wernli KJ, Beaber EF. Receipt of colonoscopy following diagnosis of advanced adenomas: an analysis within integrated healthcare delivery systems. *Cancer Epi Biomarkers & Prevention* 2019; 28(1): 91-98.
104. Feng Z, Marrero JA, Khaderi S, **Singal AG**, Kanwal F, Loo N, Beretta L, Ning J, El-Serag H. Design of the Texas Hepatocellular Carcinoma Consortium Cohort Study. *Am J Gastro* 2019; 114(3): 530-2.
105. Choi DT, Kum H, Park S, Ohsfeldt RL, Parikh ND, **Singal AG**. Hepatocellular Carcinoma Screening is Associated with Increased Survival of Patients with Cirrhosis. *Clinical Gastroenterology Hepatology* 2019; 17(5): 976-987.
106. Van der Pol CB\*, Lim CS\*, Sirlin CB, McGrath TA, Salameh J, Bashir MR, Tang A, **Singal AG**, Costa AF, Fowler K, McInnes M. Accuracy of the Liver Imaging Reporting and Data System on Computed Tomography and Magnetic Resonance Imaging – A Systematic Review. *Gastroenterology* 2019; 156(4): 976-986.
107. Murphy CC, Ahn C, Pruitt SL, Hughes AE, Halm EA, Gupta S, Santini NO, McCallister K, Sanders JM, Skinner CS\*, **Singal AG\***. Screening initiation with FIT or colonoscopy: post-hoc analysis of a pragmatic, randomized trial *Preventive Medicine* 2019; 118: 332-335.
108. Konerman M, Verma A, Zhao B, **Singal AG**, Lok AS, Parikh ND. Frequency and Outcome of Abnormal Imaging Impact in Patients with Cirrhosis Enrolled in a Hepatocellular Carcinoma Surveillance Program. *Liver Transplantation* 2019; 25(3): 369-379.
109. Setoodeh S, Liu L, Boukhar SA, **Singal AG**, Westerhoff M, Waljee AK, Ahmed T, Gopal P. The Clinical Significance of Crohn Disease Activity at Resection Margins. *Archives Pathology and Laboratory Medicine* 2019; 143(4): 505-9.

110. **Singal AG**, Rich NE, Mehta N, Branch A, Pillai A, Maarouf Hoteit, Volk M, Odewole M, Scaglione S, Guy J, Said A, Feld JF, John BV, Frenette C, Mantry P, Rangnekar AS, Olorunoba O, Leise M, Jou JH, Bhamidimarri KR, Kulik L, Tran T, Samant H, Dhanasekaran R, Duarte-Rojo A, Salgia R, Eswaran S, Jalal P, Flores A, Satapathy SK, Wong R, Huang A, Misra S, Schwartz M, Mitrani R, Nakka S, Noureddine W, Ho C, Konjeti VR, Dao A, Nelson K, Delarosa K, Rahim U, Mavuram M, Xie J, Murphy CC\*, Parikh ND\* Direct Acting Antiviral Therapy is not Associated with Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study. *Gastroenterology* 2019; 156(6): 1683-92.
111. Konerman M, Rogers M, Kenney B, **Singal AG**, Tapper EB, Sharma P, Saini SD, Nallamotheu BK, Waljee AK. Opioid and Benzodiazapene prescriptions Among Patients with Cirrhosis Compared to Other Forms of Chronic Disease. *BMJ Open* 2019; 6: e000271
112. Choi C, **Singal AG**, Padhya K, Flores A, Bursetin E, Ahmed T. Hispanic Ethnicity is Associated with Milder Disease Severity in Crohn's Disease but not Ulcerative Colitis. *Current Trends in Gastroenterology and Hepatology* 2019; 2(2): e000132
113. Choi E, Kikuchi S, Gao H, Brodzik K, Nassour I, Yopp A, **Singal AG**, Zhu H, Yu H. Mitotic regulators and the SHP2-MAPK pathway promote IR endocytosis and feedback regulation of insulin signaling. *Nature Communications* 2019; 10(1): 1473
114. Zhu M, Lu T, Jia Y, Luo X, Gopal P, Li L, Odewole M, Renteria V, **Singal AG**, Jang Y, Ge K, Wang S, Sorouri M, Parekh JR, MacConmara MP, Yopp AC, Wang T, Zhu H. Somatic mutations in cirrhosis drive clonal expansion in chronic liver disease. *Cell* 2019; 177(3): 608-621.
115. Turner BJ, Wang C, Melhado TV, Bobadilla R, Jain M, **Singal AG**. Significant increase in risk of fibrosis or cirrhosis at HCV diagnosis for Hispanics with diabetes and obesity compared with other ethnic groups. *Clinical Gastroenterology Hepatology* 2019; 17(7): 1356-63.
116. Tavakkoli A, **Singal AG**, Waljee AK, Scheiman JM, Murphy C, Pruitt SL, Xuan L, Kwon RS, Law RJ, Elta GH, Wright-Slaughter P, Valley TS, Kubiliun N, Nathan H, Rubenstein J, Elmunzer BJ. Regional and racial variations in utilization of endoscopic retrograde cholangiopancreatography among pancreatic cancer patients in the United States. *Cancer Medicine* 2019; 8(7): 3420-27.
117. Jain MK, Rich NE, Ahn C, Turner BJ, Sanders JM, Adamson B, Quirk L, Perryman P, Santini NO, **Singal AG**. Evaluation of a multifaceted intervention to reduce health disparities in hepatitis C screening: a pre-post analysis. *Hepatology* 2019; 70(1): 40-50.
118. Parikh ND, Marrero WJ, Wang Y, Steuer J, Tapper E, Konerman M, **Singal AG**, Hutton D, Byon E, Lavieri M. Projected increase in obesity and non-alcoholic steatohepatitis-related liver transplantation waitlist additions in the United States. *Hepatology* 2019; 70(2): 487-95.
119. Hester CA\*, Karbhari N\*, Rich NE, Augustine M, Mansour J, Polanco P, Porembka M, Wang S, Zeh HJ, Yopp AC\*, **Singal AG\***. Effect of fragmentation of cancer care on treatment use and survival in hepatocellular carcinoma. *Cancer* 2019; 125(19): 3428-3436.
120. Burnett-Hartman AN, Kamineni A, Corley D, **Singal AG**, Halm EA, Rutter CM, Chubak J, Lee JK, Doubeni CA, Inadomi JM, Doria-Rose P, Zheng Y. Colonoscopy indication algorithm performance across diverse healthcare systems in the PROSPR Consortium. *eGEMS* 2019; 7(1): 37
121. Liang J, Zhu J, Wang M, **Singal AG**, Odewole M, Kagan S, Renteria V, Liu S, Parikh N, Lubman D. Evaluation of AGP Fucosylation as a Marker for Hepatocellular Carcinoma of Three Different Etiologies. *Scientific Reports* 2019; 9(1): 11580.

122. Ioannou G, Beste LA, Green PK, **Singal AG**, Tapper EB, Waljee AK, Sterling RK, Feld JJ, Kaplan DE, Taddei TH, Berry K. Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years after HCV Eradication in Patients with Baseline Cirrhosis or High FIB-4 Scores. *Gastroenterology* 2019; 157(5): 1264-78.
123. **Singal AG**, Rich NE, Mehta N, Branch A, Pillai A, Maarouf Hoteit, Volk M, Odewole M, Scaglione S, Guy J, Said A, Feld JF, John BV, Frenette C, Mantry P, Rangnekar AS, Oloruntoba O, Leise M, Jou JH, Bhamidimarri KR, Kulik L, Ioannou G, Huang A, Tran T, Samant H, Dhanasekaran R, Duarte-Rojo A, Salgia R, Eswaran S, Jalal P, Flores A, Satapathy SK, Kagan S, Gopal P, Wong R, Parikh ND\*, Murphy CC\*. Direct Acting Antiviral Therapy for HCV Infection is Associated with Increased Survival in Patients with a History of Hepatocellular Carcinoma. *Gastroenterology* 2019; 157(5): 1253-63.
124. Mokdad A, Zhu H, Beg M, Arriaga Y, Dowell J, **Singal AG**, Yopp AC. Efficacy and Safety of Baviximab in Combination with Sorafenib in Advanced Hepatocellular Carcinoma: A Single-Arm, Open-Label, Phase II Clinical Trial. *Targeted Oncology* 2019; 14(5): 541-50.
125. Skinner CS, Ahn C, **Singal AG**, Nair RG, Halm EA, Pechero W, McCallister, K, Sanders JM, Farrell D, Santini N. Outcomes associated with use of Cancer Risk Intake System among primary care safety-net patients identified in needing colorectal cancer screening. *Preventive Med Reports* 2019; 16: 101003
126. Hester CA, Rich NE, Yopp AC\*, **Singal AG\***. Comparative analysis of nonalcoholic steatohepatitis- versus viral hepatitis- and alcohol-related liver disease-related hepatocellular carcinoma. *J National Comprehensive Cancer Network* 2019; 17(4): 322-329.
127. Rich NE, Yopp AC, Murphy CC\*, **Singal AG\***. Hepatocellular carcinoma Incidence is Decreasing among Younger Adults in the United States. *Clinical Gastroenterology Hepatology* 2020; 18(1) 242-248.
128. Tavakkoli A, **Singal AG**, Waljee AK, Elmunzer BJ, Pruitt SL, McKey R, Rubenstein J, Scheiman JM, Murphy CC. Racial Disparities and Trends in Pancreatic Cancer Incidence and Mortality in the United States. *Clinical Gastroenterology Hepatology* 2020; 18(1): 171-8.
129. Tincopa M, Kenney B, Tapper EB, Sharma P, Rogal S, Mellinger J, Saini S, Nallamotheu B, Waljee AK\*, **Singal AG\***. Prescription opioid use is common and associated with worse clinical outcomes in individuals with chronic liver disease. *GastroHep* 2020; 2(1): 13-21
130. Khatri G, Pedrosa I, Ananthkrishnan L, Diaz de Leon A, Fetzer DT, Leyendecker J, Xi Y, **Singal AG**, Yopp A, Yokoo T. Abbreviated-protocol screening MRI versus complete-protocol diagnostic MRI for detection of hepatocellular carcinoma in patients with cirrhosis – an equivalence study using LI-RADS v2018. *Journal of Magnetic Resonance Imaging* 2020; 51(2): 415-25.
131. Yokoo T, **Singal AG**, Diaz de Leon A, Ananthkrishnan L, Fetzer DT, Pedrosa I, Khatri G. Prevalence and clinical impact of discordant liver observation LI-RADS reporting among abdominal radiologists on multiphase contrast-enhanced MRI in patients with cirrhosis. *Abdominal radiology* 2020; 45(1): 177-87.
132. Murphy CC, Sen A, Sigel B, Gupta S, Mayo H, **Singal AG**. A systematic review of repeat fecal occult blood tests for colorectal cancer screening. *Cancer Epi Biomarkers Prev* 2020; 29(2): 278-87.

133. Chen Y, Lee, JY, Sridhar S, Mittal V, McCallister K, **Singal AG**. Improving cancer outreach effectiveness through targeting and economic assessments: insights from a randomized field experiment. *Journal of Marketing* 2020; 84(3): 1-27.
134. Rich NE, Yang JD, Perumalswami P, Alkhouri N, Jackson W, Parikh ND, Mehta N, Salgia R, Duarte-Rojo A, Kulik L, Rakoski M, Said A, Oloruntoba O, Ioannou G, Hoteit M, Moon AM, Rangnekar AS, Eswaran S, Zheng E, Jou J, Hanje J, Pillai A, Hernaez R, Wong R, Scaglione S, Samant H, Kapuria D, Chanda S, Rosenblatt R, Ajmera V, Frenette C, Sataphathy S, Mantry P, Jalal P, John B, Fix O, Leise M, Lindenmayer C, Flores A, Patel N, Jiang ZG, Latt N, Dhanasekharan R, Odewole M, Kagan S, Marrero J, **Singal AG**. Provider attitudes and practice patterns for direct-acting antiviral therapy for patients with hepatocellular carcinoma. *Clinical Gastroenterology Hepatology* 2020; 18(4): 974-83.
135. Chen VL, **Singal AG**, Tapper EB, Parikh ND. Hepatocellular carcinoma surveillance, early detection and survival in a privately-insured US cohort. *Liver International* 2020; 40(4): 947-55.
136. Scaglione S, Adams W, Caines A, Devlin P, Mittal S, Parikh N\*, **Singal AG\***. Association between race/ethnicity and insurance status with outcomes in patients with hepatocellular carcinoma. *Digestive Diseases and Sciences* 2020; 65(6): 1669-78.
137. Lin YH, Zhang S, Zhu M, Lu T, Chen K, Wen Z, Wang S, Xiao G, Luo D, Jia y, Li L, MacConmara M, Hoshida Y, **Singal AG**, Yopp A, Wang T, Zhu H. Mice with increased numbers of polyploid hepatocytes maintain regenerative capacity but develop fewer tumors following chronic liver injury. *Gastroenterology* 2020; 158(6): 1698-1712.
138. McDevitt JL, Collard M, Sutphin PD, **Singal AG**, Yopp AC, Kalva SP. Comparison of radiofrequency and microwave ablation and identification of risk factors for primary treatment failure and local progression. *Clinical Imaging* 2020; 67: 146-151.
139. Higashi R, Jain M, Quirk L, Rich NE, Waljee AK, Turner B, Lee SC\*, **Singal AG\***. Patient and Provider-Level Barriers to Hepatitis C Screening and Linkage to Care: A Mixed-Methods Evaluation. *J Viral Hepatitis* 2020; 27(7): 680-89.
140. John BV, Aubuchon S, Dahman B, Konjeti VR, Heuman D, Hubert J, Thomas S, Deng Y, Soloman C, Sundaram LT, Love E, **Singal AG**, Tatum J. Addition of 18F-FDG PET/CT to Cross-Sectional Imaging Improves Staging and Alters Management in Hepatocellular Carcinoma. *Liver Transplantation* 2020; 26(6): 774-84.
141. Rich NE, Murphy CC, Yopp AC, Tiro J, Marrero JA, **Singal AG**. Sex Disparities in Presentation and Prognosis of Patients with Hepatocellular Carcinoma. *Alimentary Pharmacology and Therapeutics* 2020; 52(4): 701-709
142. El-Serag H, Kanwal F, Feng Z, Marrero JA, Khaderi S, Beretta L, Loo N, **Singal AG**. Risk factors for cirrhosis in contemporary hepatology practices: findings from the Texas Hepatocellular Carcinoma Consortium Cohort (THCCC). *Gastroenterology* 2020; 159(1): 376-7.
143. Murphy CC, Halm E, Skinner CS, Balasubramanian B, **Singal AG**. Challenges and approaches to repeat fecal immunochemical test for colorectal cancer screening. *Cancer Epi Biomarker Prev* 2020; 29(8): 1557-63.
144. Faqih A, **Singal AG**, Fullington H, Hewitt B, Burstein E, Gopal P, Wylie A, Abrams J, Murphy CC. Colorectal neoplasia among patients with and without human immunodeficiency virus. *Cancer Epi Biomarker Prev* 2020; 29(8): 1689-91

145. Ioannou GN, Tang W, Beste L, Tincopa M, Su G, Van T, Tapper E, **Singal AG**, Zhu J, Waljee AK. Assessment of a Deep Learning Model to Predict Hepatocellular Carcinoma in Patients with Hepatitis C Cirrhosis. *JAMA Network Open* 2020; 3(9): e2015626.
146. Yang JD, Luu M, **Singal AG**, Noureddin M, Kuo A, Ayoub WS, Sundaram V, Kotler H, Kim I, Todo T, Voidonikolas G, Brennan T, Kosari K, Klein A, Hendifar A, Lu S, Nissen N, Gong J. Factors Associated with Detection and Survival of T1 Hepatocellular Carcinoma in the United States: National Cancer Database Analysis. *J National Comprehensive Cancer Network* 2020; 18(9): 1210-1220.
147. Zhu J, Huang J, Zhang J, Chen Z, Lin Y, Gigorean G, Li K, Liu S, **Singal AG**, Parikh ND, Lubman D. Glycopeptide Biomarkers in Serum Haptoglobin for Hepatocellular Carcinoma Detection in Patients with Non-Alcoholic Steatohepatitis. *J Proteome Research* 2020; 19(8): 3452-66.
148. Liu P-H, Hsu C-Y, Su C-W, Huang Y-H, Hou M-C, Rich NE, Fujiwara N, Hoshida Y, Huo T-I\*, **Singal AG\***. Thrombocytosis is associated with worse survival in patients with hepatocellular carcinoma. *Liver International* 2020; 40(10): 2522-34.
149. Zhu M, Li L, Yoo H, Zhu J, Gopal P, Wang S, Porempka M, Rich NE, Kagan S, Odewole M, Renteria V, Waljee AK, Wang T, **Singal AG**, Yopp AC, Zhu H. Uncovering biological factors that regulate hepatocellular carcinoma growth using patient derived xenograft assays. *Hepatology* 2020; 72(3): 1085-1101
150. **Singal AG\***, Parikh ND\*, Hutton DW, Tapper EB. Cost effectiveness of hepatocellular carcinoma surveillance: An assessment of benefits and harms. *Am J Gastro* 2020; 115(10): 1642-49.
151. Rich NE, John BV, Parikh, ND, Rowe I, Mehta N, Khatri G, Thomas SM, Anis M, Mendiratta-Lala M, Hernandez C, Odewole M, Sundaram LT, Konjeti VR, Shetty S, Shah T, Zhu H, Yopp A, Hoshida Y, Yao FY, Marrero JA, **Singal AG**. Hepatocellular carcinoma demonstrates heterogeneous growth patterns in a multicenter cohort of patients with cirrhosis. *Hepatology* 2020; 72(5): 1654-65.
152. Sumarsono A\*, Wang J\*, Xie L, Chiang G, Tielleman T, Messiah S, **Singal AG**, Mufti A, Chen C, Leveno M. Prognostic value of hypochloremia in critically ill patients with decompensated cirrhosis. *Critical Care Medicine* 2020; 48(11): e1054-e1061.
153. Dharwadkar P, Greenan G, **Singal AG**, Murphy CC. Is colorectal cancer in patients younger than 50 years the same disease as in older patients? *Clinical Gastroenterology Hepatology* 2021; 19(1): 192-4.e3
154. Tavakkoli A, Elmunzer BJ, Waljee AK, Murphy CC, Pruitt SL, Zhu H, Rong R, Kwon RS, Scheiman J, Rubenstein JH, **Singal AG**. Survival Analysis Among Unresectable Pancreatic Adenocarcinoma Patients Undergoing Endoscopic or Percutaneous Interventions. *Gastrointestinal Endoscopy* 2021; 93(1): 154-62.e5.
155. Gu P, Yang E, Chittajallu P, McNeill C, **Singal AG**, Kwon J, Ahmed T. Patient perception and clinical impact of direct-to-consumer advertising in inflammatory bowel disease. *Dig Dis Sci* 2021; 66(1): 63-69.
156. Nathani P, Gopal P, Rich NE, Yopp A, Yokoo T, John B, Marrero JA, Parikh ND, **Singal AG**. Hepatocellular Carcinoma Tumor Volume Doubling Time: A Systematic Review and Meta-Analysis. *Gut* 2021; 70(2): 401-7.



157. Weinheimer-Haus E\*, Yu X\*, **Singal AG**, Naylor K, Ammori C, Nailamothu B, Witala W, Zhu J, Waljee AK. Utilizing public health data to geotarget hepatitis C virus elimination approaches in urban and rural Michigan. *J Viral Hepatitis* 2021; 28(2): 440-4.
158. Wolf E, Rich NE, Marrero JA, Parikh ND, **Singal AG**. Use of hepatocellular carcinoma surveillance in patients with cirrhosis: A systematic review and meta-analysis. *Hepatology* 2021; 73(2): 713-25.
159. Cabrera R, **Singal AG**, Colombo M, Kelley RK, Lee H, Mospan AR, Meyer T, Newell P, Parikh ND, Sangro B, Reddy R, Watkins S, Zink R, Di Bisceglie A. A Real-World Observational Cohort of Patients with Hepatocellular Carcinoma (HCC): Design and Rationale for TARGET-HCC. *Hepatology Communications* 2021; 5(3): 538-47.
160. **Singal AG**, Tiro JA, Murphy CC, Blackwell J, Kramer KR, Khan A, Liu Y, Zhang S, Phillips J, Hernaez R. Patient-reported barriers are associated with receipt of hepatocellular carcinoma surveillance in a multi-center cohort of patients with cirrhosis. *Clinical Gastroenterology Hepatology* 2021; 19(5): 987-995.
161. Hernaez R, Kramer J, Khan A, Phillips J, McCallister K, Chaffin K, Hernandez A, Fullington H, Ortiz C, Blackwell J, Loewen A, Liu Y, Tiro JA, Lee SC, **Singal AG**. Depression and Anxiety are Common among Patients with Cirrhosis. *Clinical Gastroenterology Hepatology* 2021
162. Kim NJ, Rozenberg-Ben-Dror K, Jacob D, Rich N, **Singal AG**, Aby E, Yang JD, Nguyen V, Pillai A, Fuchs M, Moon AM, Schroff H, Agarwal P, Perumalswami P, Chandna S, Zhou K, Patel Y, Latt N, Wong R, Duarte-Rojo A, Lindenmeyer C, Frenette C, Ge J, Mehta N, Yao F, Benhammou J, Bloom P, Leise M, Kim H, Levy C, Barnard A, Khalili M, Ioannou G. Provider attitudes toward risk-based hepatocellular carcinoma surveillance in patients with cirrhosis. *Clinical Gastroenterology Hepatology* 2021
163. **Singal AG**, Patihandia S, Obi J, Fullington H, Parikh N, Yopp AC\*, Marrero JA\*. Benefits and harms of hepatocellular carcinoma surveillance in a prospective cohort of patients with cirrhosis. *Clinical Gastroenterology Hepatology* 2021
164. Desai N, Rich NE, Jain M, Blackwell J, Murphy C, Perryman P, McBryde J, Quirk L, Clark C, Villarreal D, Waljee A, Gopal P, **Singal AG**. Randomized Clinical Trial of Inreach with or without Mailed Outreach to Promote Hepatitis C Screening in a Difficult-to-Reach Patient Population. *Am J Gastroenterology* 2021
165. Toyoda H, Hiraoka A, Olivares K, Al-Jarrah T, Devlin P, Kaneoka Y, Maeda A, Yopp AC, Parikh ND, **Singal AG**. Outcomes of Hepatocellular Carcinoma Detected During Surveillance: Comparing USA and Japan. *Clinical Gastroenterology Hepatology* 2021
166. Rao A\*, Rich NE\*, Marrero JA, Yopp AC, **Singal AG**. Diagnostic and Therapeutic Delays in Patients with Hepatocellular Carcinoma. *Journal Nat Comp Cancer Network* 2021
167. Dharwadkar P, Greenan G, Stoffel EM, Burstein E, Pirzadeh-Miller S, Lahiri S, Mauer C, Murphy CC\*, **Singal AG\***. Racial and ethnic disparities in germline genetic testing of patients with young-onset colorectal cancer. *Clinical Gastroenterology Hepatology* 2021
168. Rich NE, Carr C, Yopp AC, Marrero JA, **Singal AG**. Racial and ethnic disparities in survival among patients with hepatocellular carcinoma in the United States: A systematic review and meta-analysis. *Clinical Gastroenterology Hepatology* 2021
169. **Singal AG\***, Woolen SA\*, Davenport MS, Troost JP, Khalatbari S, Mittal S, Siddiqui S, Fobar A, Morris A, Odewole M, Tapper E, Pillai A\*, Parikh ND\*. Patient Preferences for Hepatocellular

Carcinoma Surveillance Parameters: A MultiCenter Conjoint Study. *Clinical Gastroenterology Hepatology* 2021

170. Vajravelu RK, Kolb JM, Thanawala SU, Scott FI, Han S, **Singal AG**, Falk GW, Katzka DA, Wani S. Prevalent Esophageal Cancer Incidence Rates, Patient Factors, and Healthcare Utilization among Individuals with Barrett's Esophagus in the United States: A Large Retrospective Cohort Study. *Clinical Gastroenterology Hepatology* 2021
171. Sapena V, Enea M, Torres F, Celsa C, Rios J, Rizzo G, Nahon P, Marino Z, Tateishi R, Minami T, Sangiovanni A, Fornis X, Toyoda H, Brillanti S, Conti F, Degasperi E, Yu M-L, Tsai P-C, Jean K, El Kassas M, Shousha H, Abdelaziz A, Zavaglia C, Nagata H, Nakagawa M, Asahina Y, **Singal AG**, Murphy C, Kohla M, Masetti C, Dufour J-F, Merchante N, Cavalletto L, Chemello L, Pol S, Crespo J, Callega J, Villani R, Serviddio G, Zanetto A, Shalaby S, Russo F, Bielen B, Trevisani F, Camma C, Bruix J, Cabbibo G, Reig M. Hepatocellular Carcinoma Recurrence after Direct Acting Antiviral Therapy: An Individual Patient Data Meta-Analysis. *Gut* 2021
172. **Singal AG**, Chen Y, Sridhar S, Mittal V, Fullington H, Shaik M, Waljee AK, Tiro J. Novel Application of Predictive Modeling: A Tailored Approach to Promoting HCC Surveillance in Patients with Cirrhosis. *Clinical Gastroenterology Hepatology* 2021
173. Fujiwara N, Kobayashi M, Fobar A, Hoshida A, Marquez C, Koneru B, Panda G, Taguri M, Qiang T, Raman I, Li Q-Z, Hoshida H, Sezaki H, Kumada H, Tateishi R, Yokoo T, Yopp A, Chung R, Fuchs B, Baumert T, Marrero JA, Parikh ND, **Singal AG**, Hoshida Y. A blood-based prognostic liver secretome signature and long-term hepatocellular carcinoma risk in advanced liver fibrosis. *MED* 2021
174. Dirchwolf M, Marciano S, Ruf A, **Singal AG**, D'Ercole V, Coisson P, Zerega A, Orozco F, Palazzo A, Fassio E, Arufe D, Anders M, D'Amico C, Gaite L, Thompson M, Perez D, Haddad L, Demirdjian E, Zunino M, Gadano A, Murga M, Bermudez C, Tomatis J, Grigera N, Antinucci F, Baravalle M, Gazari M, Ferreiro M, Barbero M, Curia A, Demonte M, Gualano G. Failure in all steps of hepatocellular carcinoma surveillance process is frequent in daily practice. *Annals of Hepatology* 2021
175. Lee, Y-T, Wang J, Luu M, Tseng H-R, Rich NE, Lu S, Nissen N, Nouredin M, **Singal AG**, Yang JD. State-level hepatocellular carcinoma incidence and association with obesity and physical activity in the United States. *Hepatology* 2021
176. Govolan R, Lauzon M, Luu M, Ahn J, Kosari K, Todo T, Kim I, Nouredin M, Kuo A, Walid A, Sundaram V, Lu S, Roberts L, **Singal AG**, Heimbach J, Agopian V, Nissen N, Yang JD. Comparison of Surgical and Systemic Treatment for Hepatocellular Carcinoma with Vascular Invasion: National Cancer Database analysis. *Liver Cancer* 2021
177. Pirasteh A, Sorra EA, Marquez H, Sibley C, Yopp AC, Arroyo A, Rich NE, Fielding J, Vij A, **Singal AG**, Yokoo T. LI-RADS Treatment Response Algorithm after First-line DEB-TACE: Reproducibility and Prognostic Value at Initial Post-Treatment CT/MRI. *Abdominal Radiology* 2021
178. Ahn J, Lauzon M, Luu M, Nouredin M, Ayoub W, Kuo A, Sundaram V, Friedman M, Steinberger J, Lipshutz HG, Miles S, Hendifar A, Gong J, Kosari K, Lu S, Nissen N, Roberts L, **Singal AG**, Yang JD. Transarterial radioembolization versus systemic treatment for hepatocellular carcinoma with macrovascular invasion: Analysis of the US National Cancer Database. *Journal of Nuclear Medicine* 2021

179. Fujiwara N, Fobar A, Raman I, Li Q-Z, Marrero JA, Parikh ND, **Singal AG**, Hoshida Y. A blood-based prognostic liver secretome signature predicts long-term risk of hepatic decompensation in cirrhosis. *Clinical Gastroenterology and Hepatology* 2021
180. Cotter TG, Wang J, Lieber S, Rich NE, Marrero JA, **Singal AG**, Mitchell MC, Aronsohn A, Charlton M, Fung J. Raising HOPE: Improved Outcomes for HIV/HCV Coinfected Liver Transplant Recipients in the Direct-Acting Antiviral Era. *Transplantation Direct* 2021
181. **Singal AG**, Nagar SP, Hitchens A, Davis KL, Iyer S. Real-world effectiveness of Lenvatinib monotherapy among unresectable hepatocellular carcinoma patients in the US. *Future Oncology* 2021
182. Marquardt P\*, Liu P-H\*, Immergluck J, Olivares J, Arroyo A, Rich NE, Parikh ND, Yopp AC. **Singal AG**. Hepatocellular carcinoma screening process failures in patients with cirrhosis. *Hepatology Communications* 2021
183. Narasimhan M, Mahimainathan L, Araj E, Clark A, Markantonis J, Green A, Xu J, SoRelle J, Alexis C, Fankhauser K, Parikh H, Wilkinson K, Reczek A, Kopplin N, Yekkaluri S, Balani J, Thomas A, **Singal AG**, Sarode R, Muthukumar A. Clinical evaluation of the Abbott Alinity SARS CoV-2 spike-specific IgG and IgM assays among infected, recovered, and vaccinated groups. *Journal of Clinical Microbiology* 2021
184. Narasimhan M, Mahimainathan L, Araj E, Clark AE, Wilkinson K, Yekkaluri S, Tiro J, Lee F, Balani J, Sarode R, Muthukumar A\*, **Singal AG\***. Expanding the COVID-19 vaccine availability: Role for combined orthogonal antibody testing (COST). *Vaccines* 2021
185. Rich NE\*, Parvathaneni A\* Sen A, Odewole M, Arroyo A, Mufti A, Kerr T, Grant L, Tujios S, Mayo M, Lee, W, Yang JD, Yokoo T, Gopal P, Hoshida Y, Zhu H, Yopp A, Marrero J, **Singal AG**. High Neutrophil-Lymphocyte Ratio is Associated with Increased Mortality in Patients with Hepatocellular Carcinoma. *Digestive Diseases and Sciences* 2021
186. Lee Y-T, Wang J, Luu M, Noureding M, Kosari K, Agopian V, Rich NE, Lu S, Tseng H, Nissen N, **Singal AG**, Yang JD. The mortality and overall survival trends of primary liver cancer in the United States. *JNCI* 2021
187. Karim M, **Singal AG**, Ohsfeldt R, Morrissey M, Kum H. Health Services Utilization, Out-of-Pocket Expenditure and Underinsurance among Insured non-Elderly Cancer Survivors in the United States, 2011-2015. *Cancer Medicine* 2021
188. Pruitt S, Gerber DE, Zhu H, Heitjan D, Maddineni B, Xiong D, **Singal AG**, Tavakkoli A, Halm E, Murphy CC. Survival of patients newly diagnosed with colorectal cancer and with a history of previous cancer. *Cancer Medicine* 2021
189. **Singal AG**, Tayob N, Mehta A, Marrero JA, Jin Q, Lau J, Parikh ND. Doylestown Plus and GALAD Demonstrate High Sensitivity for HCC Detection in Patients with Cirrhosis. *Clinical Gastroenterology and Hepatology* 2021
190. Desai N, Albahra S, Lucas E, **Singal AG**, Hammer S, Gopal P. Clinical and Histopathologic Features can Help Target Immunohistochemical Stain Use in the Diagnosis of Viral Esophagitis. *Applied Immunohistochemistry & Molecular Morphology* 2021
191. Lieber S, Kim H, Baldelli L, Nash R, Teal R, Magee G, Loissele M, Desai C, Lee S, **Singal AG**, Marrero JA, Barritt S, Evon D. What Survivorship means to Liver Transplant Recipients – Qualitative Groundwork for a Survivorship Conceptual Model. *Liver Transplantation* 2021

192. Lin Y, Zhu J, Pan L, Zhang J, Tan Z, Olivares J, **Singal AG**, Parikh ND, Lubman D. A Panel of Glycopeptides as Candidate Biomarkers for Early Diagnosis or NASH Hepatocellular Carcinoma Using a Stepped HCD Method and PRM Evaluation. *J Proteome Research* 2021
193. Schoenberger H\*, Lugon N\*, Fetzer D, Rich NE, Yokoo T, Khatri, G, Olivares J, Parikh ND, Yopp AC, Marrero JA, **Singal AG**. Dynamic Changes in Ultrasound Quality for Hepatocellular Carcinoma Screening in Patients with Cirrhosis. *Clinical Gastroenterology and Hepatology* 2021
194. Lee Y-T, Wang J, Luu M, Nouredin M, Nissen N, Patel T, Roberts L, **Singal AG**, Gores G, Yang JD. Comparison of Clinical Features and Outcomes between Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma in the United States. *Hepatology* 2021
195. Sanchez J, Jiao J, Kwan S, Veillon L, Warmoes M, Tan L, Odewole M, Rich N, Wei P, Lorenzi P, **Singal AG**, Beretta L. Lipidomic Profiles of Plasma Exosomes Identify Candidate Biomarkers for Early Detection of Hepatocellular Carcinoma in Patients with Cirrhosis. *Cancer Prevention Research* 2021
196. Govalan R, Luu M, Lauzon M, Kosari K, Ahn J, Rich NE, Nissen N, Roberts LR, **Singal AG**, Yang JD. Therapeutic underutilization and delay in hepatocellular carcinoma: prevalence, associated factors and clinical impact. *Hepatology Communications* 2021

#### **Reviews, Chapters, Monographs and Editorials**

1. **Singal A** and Marrero JA. Screening for Hepatocellular Carcinoma. *Gastroenterology and Hepatology* 2008; 4(3): 1-8.
2. **Singal A**, Welling TW, Marrero JA. Role of Liver Transplantation in the Treatment of Cholangiocarcinoma. *Expert Rev Anticancer* 2009; 9(4): 491-502.
3. Volk ML, Piette JD, **Singal AG**, Lok AS. Chronic disease management for patients with cirrhosis. *Gastroenterology* 2010; 139(1): 14-16.
4. **Singal AG** and Marrero JA. Recent Advances in the Treatment of Hepatocellular Carcinoma. *Current Opinion in Gastroenterology* 2010; 26(3): 189-195.
5. **Singal AG** and Marrero JA. Interferon Therapy and Prevention of Hepatocellular Carcinoma in Hepatitis C. *Digestive Diseases and Sciences* 2012; 57(4): 832-4.
6. Max JB, **Singal AG**, Waljee AK. Stepping out with IBD: Can we take the road less travelled? *Gastroenterology* 2012; 143(2): 498-9.
7. Patel N and **Singal AG**. Hepatocellular Carcinoma Surveillance: Is a Shorter Interval Better? *Gastroenterology* 2012; 143(4): 1113-4.
8. Mayorga C, Yopp AC, and **Singal AG**. Hepatocellular Carcinoma Surveillance: All Cirrhotics May Not Be Equal. *Gastroenterology* 2012; 143(5): 1393-5.
9. Rahimi B and **Singal AG**. Current Issues and Future Trends in Surveillance for Hepatocellular Carcinoma. *Clinical Liver Disease* 2012; 1(6): 186–189.
10. Yopp A and **Singal AG**. Laparoscopic Liver Resection for Hepatocellular Carcinoma. *Clinical Liver Disease* 2012; 1(6): 206-208.
11. **Singal AG**, Tiro JA, Gupta S. Improving Hepatocellular Carcinoma Screening: Applying lessons from colorectal cancer screening. *Clinical Gastroenterology & Hepatology* 2013; 11(5): 472-7.

12. Padhya K, Marrero JA, **Singal AG**. Recent Advances in the Treatment of Hepatocellular Carcinoma. *Current Opinion in Gastroenterology* 2013; 29(3): 285-92.
13. Hassett M, Yopp AC, and **Singal AG**. Surveillance for Hepatocellular Carcinoma: How Can We Do Better? *American J Medical Sciences* 2013; 346(4): 308-13.
14. Mayorga C and **Singal AG**. Can Chronic Disease Management Programs Improve Outcomes in Patients with Cirrhosis? *Gastroenterology* 2013; 145(5): 1153-5.
15. Lee T, **Singal AG**, Sussman J, Waljee AK. At the Heart of Inflammatory Bowel Diseases. *Gastroenterology* 2013; 145(6): 1486-8.
16. Salgia R and **Singal AG**. Hepatocellular Carcinoma and Other Liver Lesions. *Medical Clinics* 2014; 98(1): 103-18.
17. **Singal AG**, Higgins PDR, Waljee AK. A Primer on Effectiveness and Efficacy Trials. *Clinical and Translational Gastroenterology* 2014; 5: e45.
18. Patel A, Max J, **Singal AG**, Waljee AK. Herpes Zoster and IBD: Are we Being Brash About a Rash? *Gastroenterology* 2014; 146(2): 576-7.
19. Knudsen E, Gopal P, **Singal AG**. The Changing Landscape of Hepatocellular Carcinoma: Etiology, Genetics & Therapy. *American Journal of Pathology* 2014; 184: 574-83.
20. Waljee AK, Higgins PDR, **Singal AG**. A Primer on Predictive Models. *Clinical and Translational Gastroenterology* 2014; 5: e44.
21. Tian C and **Singal AG**. Diagnostic paracentesis is associated with improved survival among hospitalized patients with cirrhosis *Gastroenterology* 2014; 146(3): 858-9.
22. Naveed M, Waljee AK, **Singal AG**. Predictive Models for Hepatocellular Carcinoma. *Gastroenterology* 2014; 146(5): 1420-1.
23. Yopp A and **Singal AG**. Epithelial to mesenchymal transition expression profiles as predictive biomarkers of recurrence following resection of HCC: Implications for current clinical use and future stratification for systemic therapy. *Annals of Surgical Oncology* 2014; 21(12): 3723-4.
24. Yopp A, Waljee A, and **Singal AG**. Surveillance for Hepatocellular Carcinoma in Patients with Compensated Cirrhosis: Is it Beneficial? *Gastroenterology* 2014; 147(4): 935-6.
25. Rich N and **Singal AG**. Hepatocellular Carcinoma Tumor Markers: Current Role and Expectations. *Best Practice & Research Clinical Gastroenterology* 2014; 28(5): 843-53.
26. **Singal AG**, Gupta S, Lee J, Halm E, Rutter CM, Corley D, Inadomi J. Importance of Determining Indication for Colonoscopy: Implications for Practice and Policy. *Clinical Gastroenterology and Hepatology* 2014; 12(12): 1958-1963
27. Kanwal F, Volk M, **Singal AG**, Talwalker J. Improving Quality of Healthcare for Patients with Cirrhosis. *Gastroenterology* 2014; 147(6): 1204-7.
28. Tian C and **Singal AG**. Clinical Reminders for Hepatocellular Carcinoma Surveillance: An Early Step in a Long Journey. *Clinical Gastroenterology and Hepatology* 2015; 13(1): 180-2.
29. Kim AK and **Singal AG**. Health Disparities in Diagnosis and Treatment of Hepatocellular Carcinoma. *Clinical Liver Disease* 2014; 4(6): 143-145.

30. Goebel M, **Singal AG**, Nodora J, Castanada S, Martinez E, Doubeni C, Laiyemo A, Gupta S. How Can we Boost Colorectal and Hepatocellular Cancer Screening among Underserved Populations? *Current Gastroenterology Reports* 2015; 17(6): 22
31. Karnik R and **Singal AG**. To “B” or not to “B”: Efficacy of a Neonatal Hepatitis B Vaccination Program to Prevent Liver Cancer and End-Stage Liver Disease. *Gastroenterology* 2015; 148(5): 1073-5.
32. Mehta A and **Singal AG**. Hepatocellular Carcinoma Surveillance: Does AFP have a role? *Gastroenterology* 2015; 149(3): 816-7
33. **Singal AG** and El-Serag HB. Hepatocellular Carcinoma from Epidemiology to Prevention: Translating Knowledge into Practice *Clinical Gastroenterology and Hepatology* 2015; 13(12): 140-51.
34. Mokdad AA, Livingston EH, **Singal AG**, Yopp A. Liver Cancer (Hepatocellular Carcinoma). *JAMA* 2015; 314(24): 2701
35. **Singal AG**. The Efficacy and Effectiveness of Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis. *Hepatic Oncology* 2015; 2(2): 97-99.
36. Mokdad AA, Livingston EH, **Singal AG**, Yopp A. Treatment of Liver Cancer (Hepatocellular Carcinoma). *JAMA* 2016; 315(1): 100
37. Mokdad A, **Singal AG**, Yopp A. Advances in Local and Systemic Therapies for Hepatocellular Carcinoma. *Current Oncology Reports* 2016; 18(2): 9
38. Parikh N, Yopp A, and **Singal AG**. Controversies in Criteria for Liver Transplantation in HCC. *Current Opinion* 2016; 32(3): 182-8
39. Parikh N and **Singal AG**. MELD exception points for treatment responsive HCC. *Chronic Liver Disease* 2016; 7(5): 97-100
40. Parikh N and **Singal AG**. The ITA.LI.CA Staging System: A Novel Staging System for Hepatocellular Carcinoma. *PLOS Medicine* 2016; 13(4): e1002005
41. **Singal AG** and Yopp AC. Hepatocellular Carcinoma: How can we move from racial/ethnic disparities to a model of health equity? *Cancer* 2016; 122(16): 2454-56
42. Rich N, Yopp A, **Singal AG**. Medical Management of Hepatocellular Carcinoma. *Journal of Oncology Practice* 2016; 13(6): 356-64.
43. Rich N, Parikh N, **Singal AG**. Hepatocellular Carcinoma and Liver Transplantation: Changing patterns and practices. *Current Treatment Options in Gastroenterology* 2017; 15(2): 296-304
44. Yopp AC, Parikh ND, **Singal AG**. Is the Hong Kong Liver Cancer Staging System Ready to Replace the Barcelona Clinic Liver Cancer System? *Clinical Gastroenterology and Hepatology* 2017; 15(5): 756-758
45. Yopp AC, Marrero JA, **Singal AG**. Expansion of criteria for liver transplantation in hepatocellular carcinoma: Better patient selection or a slippery slope? *Annals Surgical Oncology* 2017; 24(7): 1758-60
46. Magrath M, Yang E, **Singal AG**. Personalizing colon cancer screening: Role of age and comorbid conditions. *Current Colorectal Cancer Reports* 2017; 13(3): 220-6.
47. Marrero JA and **Singal AG**. Direct acting antivirals and recurrence of hepatocellular carcinoma. *Liver Transplantation* 2017; 23(9): 1099-1100

48. Rich NE and **Singal AG**. Overdiagnosis: An understudied issue in Hepatocellular carcinoma surveillance. *Seminars in Liver Disease* 2017; 37(4): 296-304
49. **Singal AG**. Con: Hepatocellular Carcinoma Surveillance: In Need of Higher Quality Data. *Am J Gastro* 2017; 112(11): 1634-5.
50. Parvathaneni A and **Singal AG**. Hepatocellular carcinoma surveillance: A path to better effectiveness. *Oncology News* 2017; 12(3): 78-80.
51. Meyer J and **Singal AG**. Stereotactic Ablative Radiotherapy for Hepatocellular Carcinoma: History, Current Status, and Opportunities. *Liver Transplantation* 2018; 24(3): 420-7.
52. Murphy C and **Singal AG**. Establishing a research agenda for early-onset colorectal cancer. *PLOS Medicine* 2018; 15(6): e1002577
53. Fowler KJ, Hecht E, Kielar AZ, **Singal AG**, Sirlin CB. LI-RADS v2018: a primer and update for clinicians. *Current Hepatology Reports* 2018; 17(4): 425-33.
54. Chernyak V, Fowler KJ, Kamaya A, Zieler AZ, Elsayes KM, Bashir MR, Kono Y, Do RK, Mitchell DG, **Singal AG**, Tang A, Sirlin CB. Liver Imaging Reporting and Data System (LI-RADS) 2018: Imaging of Hepatocellular carcinoma (HCC) in At-Risk Patients. *Radiology* 2018; 289(3): 816-30.
55. Tzartzeva K and **Singal AG**. Testing for AFP in combination with ultrasound improves early detection of hepatocellular carcinoma. *Expert Review of Gastroenterology & Hepatology* 2018; 12(10): 947-49.
56. Tellpuri S, Sutphin PD, Beg MS, **Singal AG**, Kalva SP. Staging systems of hepatocellular carcinoma: A review. *Indian Journal of Gastroenterology* 2018; 37(6): 481-91.
57. Tang A, **Singal AG**, Mitchell DG, Hecht E, Fowler KJ, Kulik L, Parikh ND, Kono Y, Sirlin CB. Introduction to the Liver Reporting and Data System (LI-RADS) for hepatocellular carcinoma. *Clinical Gastroenterology and Hepatology* 2019; 17(7): 1228-38.
58. Kanwal F and **Singal AG**. Surveillance for Hepatocellular Carcinoma: Best Practice and Future Directions. *Gastroenterology* 2019; 157(1): 54-64.
59. **Singal AG** and Murphy CC. Hepatocellular Carcinoma: A roadmap to reduce incidence and future burden. *JNCI* 2019; 111(6): 527-8.
60. Lim J and **Singal AG**. Surveillance and Diagnosis of Hepatocellular Carcinoma. *Clinical Liver Disease* 2019 13(1): 2-5.
61. Marquardt P, Hoshida Y, **Singal AG**. Aspirin: Does it have a role for HCC chemoprevention? *Gastroenterology* 2019; 156(5): 1530-31.
62. Kubiliun M, Rich NE, Singal AG, Mufti A. PRO: Liver transplantation should be considered in select patients with acute alcoholic hepatitis. *Clinical Liver Disease* 2019; 13(5): 140-143.
63. Hanouneh I, Alkhouri N, Singal AG. Hepatocellular carcinoma surveillance in the 21<sup>st</sup> century: Saving lives or causing harm? *Clinical and Molecular Hepatology* 2019; 25(3): 264-69
64. Frenette C, Isaacson A, Bargellini I, Saab S, Singal AG. A Practical Guideline for Hepatocellular Carcinoma Screening in Patients at-Risk. *Mayo Clinic Proceedings* 2019; 3(3): 302-10.
65. Yarchoan M, Agarwal P, Villanueva A, Dawson L, Karasi T, Llovet J, Finn R, Groopman J, El-Serag H, Monga S, Wang X, Karin M, Schwartz R, Tanabe K, Roberts L, Gunaratne P, Tsung A, Brown K, Lawrence T, Salem R, **Singal AG**, Kim A, Rabjee A, Resar L, Meyer J, Hoshida Y, He

- A, Rao S, Ghoshai K ,Ryan P, Guha C, Mishra L, Coleman CN, Ahmed M. Recent Developments and Therapeutic Strategies for Hepatocellular Carcinoma. *Cancer Research* 2019; 79(17): 4326-30.
66. Fujiwara N, Singal AG, Hoshida Y. Dose and duration of aspirin use to reduce incidental hepatocellular carcinoma. *Hepatology* 2019; 70(6): 2216-7.
  67. Petrasek J, **Singal AG**, Rich NE. Harms of Hepatocellular Carcinoma Surveillance. *Current Hepatology Reports* 2019; 18: 383-9.
  68. **Singal AG**, Lampertico P, Nahon P. Epidemiology and Surveillance for Hepatocellular Carcinoma: New Trends. *J Hepatology* 2020; 72(2): 250-61.
  69. Bangaru S, Marrero JA, **Singal AG**. Review article: New Therapeutic Interventions for Advanced Hepatocellular Carcinoma. *Alimentary Pharmacology and Therapeutics* 2020; 51(1): 78-89.
  70. Verma M, Tapper EB, **Singal AG**, Navarro V. Nonhospice palliative care within the treatment of end-stage liver disease. *Hepatology* 2020; 71(6): 2149-59.
  71. Aroniadis O, DiMaio C, Dixon R, Elmunzer BJ, Kolb J, Mendelsohn R, Ordiah C, Rockey D, **Singal AG**, Spitzer R, Tierney WM, Wani S, Yadav D. Current knowledge and research priorities in the digestive manifestations of COVID-19. *Clinical Gastro and Hepatology* 2020; 18(8): 1682-4.
  72. Moon AM, **Singal AG**, Tapper EB. Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis. *Clinical Gastro and Hepatology* 2020; 18(12): 2650-66.
  73. **Singal AG**, Lim J, Kanwal F. AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review. *Clinical Liver Disease* 2020 15(6): 211-212.
  74. Onyirioha K, Mittal S, **Singal AG**. Is HCC Surveillance in High-Risk Populations Effective? *Hepatic Oncology* 2020; 7(3): HEP25
  75. Osho A, Rich NE, **Singal AG**. Role of Imaging in Management of Hepatocellular Carcinoma: Surveillance, Diagnosis, and Treatment Response. *Hepatoma Research* 2020; 6(8): 55
  76. Parikh ND, Mehta A, **Singal AG**, Block T, Marrero JA, Lok AS. Biomarkers for the Early Detection of Hepatocellular Carcinoma. *Cancer Epi Biomarkers Prevention* 2020; 29(12): 2495 – 2503.
  77. Mittal S, Gopal P, Khatri G, **Singal AG**. Evaluation and management of hepatocellular adenomas. *Clinical Liver Disease* 2021; 17(2): 57-60.
  78. Byrd K, Alqahtani S, Yopp AC, **Singal AG**. Role of Multidisciplinary Care in Management of Hepatocellular Carcinoma. *Seminars in Liver Disease* 2021
  79. Mehta N, Parikh N, Kelley RK, Hameed B, **Singal AG**. Surveillance and Monitoring of Hepatocellular Carcinoma During the COVID-19 Pandemic. *Clinical Gastro and Hepatology* 2021
  80. Ferrante ND, Pillai A, **Singal AG**. Update on the Diagnosis and Treatment of Hepatocellular Carcinoma. *GastroHep* 2021
  81. **Singal AG**, Lok AS, Feng Z, Kanwal F, Parikh ND. Conceptual Model for the Hepatocellular Carcinoma Screening Continuum: Current Status and Research Agenda. *Clinical Gastro and Hepatology* 2021



82. Llovet J, Kelley RK, Villanueva A, **Singal AG**, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J, Finn R. Hepatocellular carcinoma. *Nature Reviews Disease Primers* 2021
83. Nathani P and **Singal AG**. Imaging and Biomarker Approaches to HCC Surveillance. *Clinical Liver Disease* 2021
84. Ajayi F, Jan Jenny, **Singal AG**. Rich NE. Racial and Sex Disparities in Hepatocellular Carcinoma in the United States. *Current Hepatology Reports* 2021
85. Rich NE and **Singal AG**. Direct acting antivirals and hepatocellular carcinoma. *Clinical Liver Disease* 2021
86. **Singal AG**, Hoshida Y, Pinato DJ, Marrero JA, Nault J-C, Paradis V, Tayob N, Sherman, M, Lim YS, Feng Z, Lok AS, Rinaudo J, Srivastava S, Llovet J, Villaneuva A. International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma. *Gastroenterology* 2021
87. Rich NE, Noureddin M, Kanwal F, **Singal AG**. Racial and Ethnic Disparities in NAFLD in the US. *Lancet Gastroenterology and Hepatology* 2021

### **Books/Textbook Chapters**

1. **Singal A** and Schoenfeld P. 2008. *How do you respond to patients wanting to take aspirin, calcium, or other medications as prophylaxis for colorectal cancer? Is there any evidence that they work?* In Curbside Consultation of the Colon: 49 Clinical Questions. Thorofare: Slack Incorporated.
2. **Singal AG** and Marrero JA. 2010. *Screening for HCC in Patients with Viral Liver Disease – Is Ultrasound Enough?* In Clinical Dilemmas in Viral Liver Disease. West Sussex: Wiley-Blackwell.
3. Yopp A and **Singal AG**. 2011. *Hepatocellular Carcinoma in Clinical Decision Support: Oncology*, edited by Johnson DH, Benz EJ, Gerber DE, LaCasce AS. Decision Support in Medicine, LLC. Wilmington, DE.
4. **Singal AG** and Marrero JA. 2014. *Hepatocellular Carcinoma* in Yamada Textbook of Gastroenterology. Wiley-Blackwell.
5. **Singal AG**, Gopal P, Yopp A. 2016. *Hepatocellular Carcinoma: Epidemiology and Basic Principles of Treatment* in Radiation Therapy for Liver Cancer. Springer
6. Curley SA, Barnett CC, Abdalla EK, **Singal AG**. 2017. *Management of potentially resectable hepatocellular carcinoma: Prognosis, role of neoadjuvant and adjuvant therapy, and post-treatment surveillance*. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA.
7. **Singal AG**, Parikh ND, Rich NE, John BV, Pillai A. 2018. *Hepatocellular Carcinoma Surveillance and Staging* in Translational Precision Medicine Approaches. Springer.
8. Bangaru S, Marrero JA, **Singal AG**. *Screening for hepatocellular carcinoma in viral liver disease: Any new biomarkers on the horizon?* In Clinical Dilemmas in Viral Liver Disease. Wiley Blackwell.

### **Case Reports**

1. **Singal A**, Malani PN, Day LJ, Pagani FD, Clark NM. Roseomonas Infection Associated with a Left Ventricular Assist Device. *Infection Control and Hospital Epidemiology* 2003; 24(12): 963-965.

2. Subramanian M, **Singal AG**, Yopp, AC. Hepatocellular Carcinoma with Right Atrial Extension: Tumor Regression with Transarterial Chemoembolization and Sorafenib. *Clinical Gastroenterology and Hepatology* 2012; 19(10): E83-4.
3. Turer E, Rockey DC, **Singal AG**. A Potential Novel Use for Direct Antiviral Therapy. *Hepatology* 2013; 57(1): 414-415.
4. Khambaty M, **Singal AG**, Gopal, P. Spirochetes as an Almost Forgotten Cause of Hepatitis. *Clinical Gastroenterology and Hepatology* 2015; 13(2): A21-2.
5. Augustyn A, Peng L, **Singal AG**, Yopp AC. Surveillance for hepatocellular carcinoma secondary to cardiogenic cirrhosis in patients with congenital heart disease. *Clin Res Cardiol* 2015; 104(5): 446-9.
6. Geng Z, Agrawal D, **Singal AG**, Kircher S, Gupta S. Contained Colonic Perforation due to Cecal Retroflexion. *World J Gastroenterology* 2016; 22(11): 3285-88.

### **Letters to the Editor**

1. **Singal AG**, Thomassen LV, Gretch DR, Shuhart MC. Impact of CD4+ T-cell count on the performance of non-invasive fibrosis markers in HIV-HCV patients: authors' reply. *Alimentary Pharmacology and Therapeutics* 2011; 33(10): 1174-1175.
2. **Singal AG**, Marrero JA, Lok AS, Lee WM. Reply to Giannini and Trevisani. *American J. Gastroenterology* 2013; 108(6): 1014.
3. Gopal P and **Singal AG**. Reply to PMID 24095974. *Clinical Gastroenterology and Hepatology* 2014; 12(12): 2139-40.
4. **Singal AG**. Reply to "Screening for Hepatocellular Carcinoma: Where is the Inconsistency" *Am J Medicine* 2015; 128(3): e27
5. Simmons O, Fetzer DT, Yokoo T, Marrero JA, Yopp A, Kono Y, Parikh N, Browning T, **Singal AG**. Editorial: Ultrasound Surveillance of Hepatocellular Carcinoma in the 21<sup>st</sup> Century – authors' reply. *Alimentary Pharmacology and Therapeutics* 2017; 45(4): 562-3.
6. Parikh ND, **Singal AG**, Lok AS, Balkrishnan R, Shahinian V, Marshall VD. Reply to "Immortal time bias or sorafenib effect in elderly patients with HCC?" *Hepatology* 2017; 66(2): 679-80.
7. Atiq O, Tiro J, Yopp AC, Muffler A, Marrero JA, Parikh ND, Murphy C, McCallister K, **Singal AG**. Reply to "Unscheduled Screening Tests Cannot be Termed as Surveillance". *Hepatology* 2017; 66(3): 1002 – 3.
8. **Singal AG** and Murphy CC. Hepatocellular carcinoma surveillance: an effective but complex process. *Gastroenterology* 2019; 156(4): 1215.
9. Rich NE and **Singal AG**. Reply to "Surveillance for early-stage HCC by ultrasound plus AFP measurement: More details, more significance. *Gastroenterology* 2018; 155(4): 1275-76.
10. **Singal AG**. Reply to "Historical Data are not relevant to the diagnostic performance of ultrasound in HCC surveillance." *Gastroenterology* 2019; 157(3): 901-2.
11. **Singal AG**, Parikh ND, Murphy CC. Reply to Gastro D-19-02722. *Gastroenterology* 2020; 158(6): 1844
12. **Singal AG**, Lampertico P, Nashon P. Reply to Challenges associated with roll-out of HCC surveillance in sub-Saharan Africa – the case of Uganda. *J Hepatology* 2020; 73(5): 1273-4.

13. Rich NE, Marrero J, **Singal AG**. Reply: Wang et al, “Should growth pattern of hepatocellular carcinoma be constant and homogenous?” *Hepatology* (in press)
14. Rich NE, Parikh ND, **Singal AG**. HCC Surveillance in Cirrhosis Patients: Room for Improvement. *Hepatology* (in press)

### **Clinical Practice Guidelines**

1. **Singal AG**, Lim JK, Kanwal F. AGA Clinical Practice Update: Interaction between oral direct acting antivirals (DAAs) for chronic hepatitis C infection and hepatocellular carcinoma. *Gastroenterology* 2019; 156(8): 2149-57.
2. Gupta S, Coronado GD, Argenbright K, Brenner AT, Castaneda SF, Dominitz J, Green B, Issaka RB, Levin TR, Reuland DS, Richardson LC, Robertson DJ, **Singal AG**, Pignone M. Mailed Fecal Immunochemical Test Outreach for Colorectal Cancer Screening: Summary of a Center for Disease Control-Sponsored Summit. *CA: A Cancer Journal for Clinicians* 2020; 70(4): 283-98.

### **Non-peer reviewed scientific or medical publications/materials in print or other media**

1. **Singal A** and Shuhart M. Treatment Regimens for Chronic Hepatitis C Virus Infection. In Marrazzo J, Spach DH. *Hepatitis Web Study* [<http://depts.washington.edu/hepstudy>] 2006
2. **Singal AG** and Parikh ND. What is impact of HCV therapy on the incidence and recurrence of HCC? *AGA Perspectives* 2018
3. **Singal AG**. Association between Steatohepatitis Biomarkers and Hepatocellular Carcinoma after Hepatitis C Elimination. [www.PracticeUpdate.com](http://www.PracticeUpdate.com) Available at: <https://www.practiceupdate.com/content/association-between-steatohepatitis-biomarkers-and-hcc-after-hcv-elimination/105218/65/9/1>. Accessed September 18, 2020